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Alkylation of DNA at the O6-position of guanine can lead to mutation and cell death.  
These DNA adducts are repaired by the repair protein MGMT (O6-methylguanine-DNA-
methyltransferase).  MGMT protein is conserved through evolution though the exact 
physiological function remains obscure.  MGMT acts by transferring the O6-alkyl group 
to the cysteine residue at position 145 at its active site.  This repair process (indirect 
alkylation), as well as direct alkylation at its active site, irreversibly inactivates the 
protein, generates active-site alkylated MGMT, R-MGMT, and hence the term ‘suicidal’ 
repair. 
 R-MGMT adopts a conformation change which renders the protein susceptible to 
protease V8 cleavage. In addition, the altered conformation exposes the domain 
surrounding the residues 91-107 containing the monoclonal antibody 3C7 recognition 
epitope. We have thus far characterized the roles of R-MGMT in regulating the cell 
growth.  We have showed that R-MGMT, with its exposed domain, containing the 
LXXLL motif, interacts directly with the estrogen receptor alpha (ERα) to repress ERα− 
mediated transcription and proliferation in cells expressing both MGMT and ERα 
proteins.  We have also identified a role of active MGMT as a potential transcription 
activator of the ERα gene.  Chromatin Immunoprecipitation (CHIP) experiments 
demonstrated the association of MGMT with ERα gene in MCF7 breast cancer cell, and 
this interaction is disrupted and displaced by BRCA1 (Breast cancer susceptibility gene) 
protein when cells are exposed to oxidative damage. These findings suggest that 
MGMT/R-MGMT play important roles in breast cancers. Furthermore, it was showed 
 x
that the domain exposed in R-MGMT shares high homology to tumour suppressor protein 
p53 and R-MGMT can interact directly with MDM2 (an oncoprotein).  By performing 
p53-degradation assay, we found that R-MGMT can inhibit the function of MDM2 as an 
ubiquitin E3 ligase and hence stabilize the p53 protein.  We have also found that the 
specific MGMT inhibitor O6 -benzylguanine (BG), which is used in early phase II 
clinical studies, can cause dephosphorylation of the serine-15 residue in p53 protein. 
Taken together, these findings describe how MGMT integrate different damage signals 
and mediate different pathway to regulate the growth of cells. 
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Chapter 1   
Introduction 
All organisms must have a means to maintain their genetic integrity due to their constant 
exposure to DNA damaging agents from exogenous as well as endogenous (Lavin and 
Shiloh, 1997) sources.  Such agents can be from the normal cellular metabolism or from 
exogenous source. Damage or modification to DNA if left unattended have deleterious 
effects, as this may lead to mutations that alter gene expression patterns and produce 
oncogenic mutant proteins which will affect the normal cell processes. Numerous 
diseases, including cancers have originated exposure to environmental mutagens coupled 
to DNA repair deficiencies, such as Xeroderma Pigmentosa, where the nucleotide 
excision pathway is defective. Other human disorders in relation to defective repair or 
failure to response to DNA damage include Trichothiodystrophy, Cockayne Syndrome, 
Fanconi’s anemia, Ataxia telengiectasia and hereditary non-polyposis colorectal cancer 
(HNPCC). Understanding how cells respond to and counteract these adverse effects of 
damaged DNA is fundamental to the origin of these diseases.   
 
1.1 Types of DNA Damages 
1.1.1 DNA instability 
DNA can be damaged in many forms due to its intrinsic instabilities or through reaction 
with endogenous or exogenous agents. The spontaneous hydrolysis of DNA N-glycosyl 
bonds resulting in the formation of abasic sites, which lost the genetic coding information 
and leads to mutations during replication (Lindahl, 1993). This hydrolysis was estimated 
to occur at a rate of 10,000 abasic sites/cell/day under physiological conditions 
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(Nakamura et al., 1998). Recently, abasic sites have been shown to induce dramatic 
triplet-repeat expansion (TRE) during DNA synthesis (Lyons-Darden and Topal, 1999).  
TRE is involved in many neurological and neuromuscular diseases including Fragile X 
syndrome and myotonic dystrophy (Ashley, Jr. and Warren, 1995; Fu et al., 1991; 
Sutherland and Richards, 1995). Furthermore, it is well accepted that hydrolytic 
deamination of exocyclic amino group of cytosine (C), 5-methylcytosine (5-meC), 
adenine (A) and guanine (G) leads to the formation of uracil (U), thymine, hypoxanthine 
and xanthine respectively, is an important source of genomic alteration, that may aid in 
evolution as well as a cause of disease. Particularly, the deamination of cytosine and 5-
methylcytosine results in mismatch pairing to guanine. The estimated rate of cytosine 
deamination ranges from 100-500 events/cell per day and will results in transition 
mutation of CGÆTA if left unrepaired (Frederico et al., 1990; Shen et al., 1994). 
 
1.1.2 Oxidative and alkylation damages 
Another major source of spontaneous DNA damage is generated via oxidation (Lindahl 
and Wood, 1999; Klungland et al., 1999).  Reactive oxygen species generated during 
chronic inflammation, from by-products of cellular metabolism, and exposure to 
environmental agents (Beckman and Ames, 1997; Loft and Poulsen, 1996) can cause 
various type of DNA modifications including etheno adducts of pyrimidines and purines  
(Marnett, 2000; Marnett and Plastaras, 2001; Nair et al., 1999). Among many forms of 
oxidative DNA lesions, 8-oxo-2'-deoxyguanosine (8-oxo-dG) represents one of the most 
abundant, about 100 to 1000 8-oxodG residues in normal cells (Klungland  et al 1999). 
This lesion is widely studied (Cheng and Diaz, 1991; Fraga et al., 1990; Le Page et al., 
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1995; Marnett, 2000; Moriya, 1993; Shibutani et al., 1991; Wagner et al., 1992) because 
8-oxodG is a premutagenic lesion that mispairs with A, generating GC to TA 
transversions (Shibutani and Grollman, 1994).  Thymine glycol, another major product of 
base oxidation (Ide et al., 1985; Rouet and Essigmann, 1985), is a lethal lesion as it 
blocks both DNA and RNA polymerases in vitro (Evans et al., 1993; Hatahet et al., 1994; 
Laval et al., 1998). 
Damage to DNA backbone via the oxidation of deoxyribose sugar can be deleterious as 
these usually results in strand breaks (Burrows and Muller, 1998). Alkylating agents 
induce significant base modification in DNA. For example, N-methyl-N-nitrosourea 
(MNU) can damage DNA at the N and O atoms and give rise to cytotoxic and mutagenic 
lesions (Singer and Grunberger, 1983). Although the most abundant 7-methylguanine 
lesions is relatively innocuous, it increases base depurination giving rise to abasic site 
which can result in mutation if by-passed by the DNA polymerase or mis-insertion during 
replication from the error-prone repair pathway (Michaels et al., 1991). The 3-
methyladenine is by far known to be the most cytotoxic as they block DNA replication 
(Klungland et al., 1992). In mammalian cells, 3-methyladenine lesions are removed by 
methylpurine DNA glycosylase (MPG/AAG/ANPG), via the multistep base excision 
repair pathway (Hollis et al., 2000). In contrast to 7-methyguanine, O6-methylguanine 
(O6–meG) and O4-methylthymine (O4-meT) are less abundant but are the most potent 
mutagenic adducts (Loechler et al., 1984; Loveless, 1969) as they result in O6–meG:T , 
or O4-meT:G mispairing during replication (Saffhill et al., 1985). These lead to G:C Æ 
A:T transitions or A:T Æ C:G tansversion  mutations. When coupled to mismatch repair 
deficiency, the  O6–meG lesion is lethal (Karran and Bignami, 1992) due to repeatedly 
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generations of the meG.T mismatch substrates by “futile” repair loop (Karran and 
Bignami, 1994).   
 
1.1.3 Irradiation Damage 
Apart from intrastrand dimerization of thymine-thymine residues by low energy UV 
radiation, high-energy source irradiation can also cause double strand breaks. Similarly, 
radiomimetic drugs such as bleomycin, which causes double strand break by generating 
clustered damage sites on DNA (Povirk, 1996). Interestingly, double strand breaks are 
also an obligatory process during replication (Cox et al., 2000; Cox, 2002; 
Kowalczykowski, 2000) and meiosis or V(D)J recombination to generate mature immune 
system (van Gent et al., 2001). Double strand breaks are known to lead to chromosomal 
aberration and cell death. 
 
1.1.4 Mutagenic Chemicals 
The last category of DNA lesions is those arise from interstrand crosslinks (ICLs). 
Crosslinks can be on the same strand of DNA (intrastrand), between the two 
complementary strands of DNA (interstrand), or between a base on DNA and a reactive 
group on a protein (DNA-protein) (Legerski and Richie, 2002; McHugh et al., 2001). A 
number of anti-tumour drugs such as chloroethyl nitrosourea, mitomycin C and cisplatin 
are known to cause ICLs.  ICLs are highly cytotoxic as they block vital DNA metabolic 
processes, such as transcription and DNA replication, which require the separation of the 
two strands. ICLs lesions are repaired via double strand break and nucleotide excision 
repair pathways.  
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All cells can sustain DNA damage from various endogenous or exogenous sources; the 
main biological response to such insults will rely on their DNA repair capacity.  In the 
following sections the main human DNA repair pathways will be discussed briefly. 
 
1.2 DNA Repair Pathways 
1.2.1 Base Excision Repair (BER) 
Modified DNA bases resulting from deamination, oxidation or alkylation are mainly 
repaired by base excision repair system (BER) (Lindahl and Wood, 1999; Gros et al., 
2002; Nilsen and Krokan, 2001; Scharer and Jiricny, 2001). Where the DNA 
glycosylases (Krokan et al., 1997) plays a major role in recognition and excision of the  
lesion from the the DNA by cleavage of the N-glycosylic bond between the abnormal 
base and deoxyribose to generate an abasic site (Lindahl and Ljungquist, 1975). APE-1 
(apurinic/apyrimidinic (AP) endonuclease) is then recruited to the abasic site to 
hydrolyze the phosphodiester bond 5’ to the AP site to generate a nick, allowing the 
polymerase   to fill the gap and subsequent resealing of DNA by ligases.  At present, nine 
DNA glycosylases have been cloned and each has unique substrate specificity.  There are 
two types of glycosylases: mono- and bifunctional.  Monofunctional glycosylases cleave 
the   N-glycosylic bond to release the modified base whereas for bifunctional ones, with 
the inherited AP lyase activity enables further to hydrolysis of the bond 3’ to the abasic 
site.  The repair is completed by APE1, Polβ and DNA ligase.   The human 
monofunctional glycosylases include uracil-DNA glycosylase (UDG) (Lindahl et al., 
1977; Nilsen et al., 1997; Olsen et al., 1989), thymine/uracil mismatch glycosylase 
(TDG) (Neddermann et al., 1996; Neddermann et al., 1996), SMUG1 (Haushalter et al., 
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1999) and MBD4 (Hendrich et al., 1999; Petronzelli et al., 2000), all of which shares the 
common substrate uracil, generated from deamination of cytosine. In contrast, 
methylpurine-DNA glycosylase MPG removes a wide range lesions such as 3-
methyladenine and 7-methylguanine (O'Connor and Laval, 1990; Vickers et al., 1993).  
Surprisingly, the bifunctional glycosylase includes hOGG1 (Radicella et al., 1997), also 
remove oxidation lesions 8-oxoG and thymine glycol by hNTH1 (Aspinwall et al., 1997; 
Ikeda et al., 1998). The difference between these glycosylases and hMYH1  (Slupska et 
al., 1996), the human MutY homologue which removes adenine from 8-oxoG/A 
mismatch, is unknown. 
There are two BER pathways in human, the ‘short-patch’ DNA polymeraseβ-dependent 
pathway (Kubota et al., 1996) and the ‘long-patch’ PCNA dependent pathway (Frosina et 
al., 1996; Klungland and Lindahl, 1997; Matsumoto et al., 1994; Matsumoto et al., 1994; 
Frosina et al., 1996; Klungland and Lindahl, 1997).   Short patch repair involves the 
replacement of a single nucleotide, while in long-patch BER involves Pol δ/ε and 
associating factors to replace up to 6 nucleotides and for excision by the  FEN-1/PCNA 
complex, followed by resealing by DNA ligase I (Wilson, III and Thompson, 1997). No 
deficiencies in BER enzymes were documented but the hMYH gene was implicated in 
familial colorectal adenomas (Al Tassan et al., 2002; Jones et al., 2002).  Only recently, 
Nfo (Endonuclease IV) and Nfo-like endonucleases were implicated as an alternative to 
the BER-mediated oxidative damage repair (Ischenko and Saparbaev, 2002). This 
pathway, nucleotide incision repair (McKenna and O'Malley, 2002b), replaces (or repair) 
the abasic sites directly unlike the long-patch BER. Moreover, this appears to be a new 
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physiological function, in which a modified base rather than an abasic site can mediate 
the long-patch repair pathway described in human cells. 
 
1.2.2    Nucleotide Excision Repair (NER) 
Bulky DNA base adducts (such as those formed by UV light, environmental mutagens, 
and chemotherapeutic agents) are removed by the NER pathway.  NER pathway is the 
most fundamental repair pathway, as life is evolved around light, to repair/remove 
photochemical lesions such as cyclobutane pyrimidines and 6-4 products produced by 
UV-radiation (Gunz et al., 1996; Balajee and Bohr, 2000). At least 30 distinct proteins 
are involved in NER where they form a large nucleotide excision repairosome complex to 
generate bimodal incisions in the flanking region of the lesion 30 nucleotides in length 
(Friedberg et al., 1995). Key steps in NER include: recognition, recruitment, positioning, 
incision, gap- filling and ligation to restore the normal DNA (Balajee et al 2000; (Wood, 
1997). There are two NER repair pathways, global genomic repair (Pike et al., 1999) and 
transcription -coupled repair (TCR), depending on where the lesion is located in non-
transcribed regions of DNA (Pike et al., 1999) or located in actively transcribing DNA 
(TCR).   TCR was first discovered based on the observation that lesions that block the 
RNA polymerases are repaired more rapidly in actively transcribing DNA (Bohr et al., 
1985; Mellon et al., 1987). With the exception of XPC/hR23B, most of the enzymatic 
steps that follow after initiation are involved in both TCR and GGR (Global Genome 
Repair) (Balajee and Bohr, 2000; Wood, 1997). TCR requires additional genes, including 
CSA and CSB. In bacterial, a stalled RNA polymerase at the DNA lesion is required to 
trigger TCR leading to strand specific repair.   
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Proteins such as p53 regulate the NER pathways. Induction of NER and apoptosis were 
observed only in cells expressing wild-type p53 (Li and Ho, 1998). The p53 effect on 
GGR is mediated through p48 (XPE, involve in damage detection) (Hwang et al., 1999; 
Tang and Chu, 2002). As p53 is involved in transactivating XPE, it controls the 
efficiency of GGR. In addition, p53 is also involved in transactivation of other genes 
implicated in early steps of NER, such as GADD45.  Loss of GADD45 results in 
deficient GGR of cyclobutane pyrimidine dimers (Smith et al., 2000).  Tumour virus 
infection such as HPV and SV40 viruses, which results in inactivation of p53, can 
correspondingly reduce the efficiency of GGR (Ford et al., 1998; Bowman et al., 2000).  
Some reports suggest a role of NER in terminally differentiated cells (Nouspikel and 
Hanawalt, 2002; Nouspikel and Hanawalt, 2002). 
Nevertheless, three rare autosomal recessive disorders, Xeroderma pigmentosum (XP), 
Cockayne syndrome (CS) and trichothiodystrophy (TTD) are associated with NER 
defects. These patients are extremely sensitive to sunlight and have a 1000 fold higher 
predisposition to skin cancer (Cleaver, 1968). XP is related to defect in XPA that 
inactivate NER. CS patients will develop neurological abnormalities, is aroused from 
mutations in CSA or CSB genes (Friedberg, 1996).  TTD patients are deficient in TCR 







1.2.3   Mismatch Repair (MMR) 
MMR proteins are responsible for the post-replication repair of improper replicated DNA 
as well as alkylating agents induced lesions and bulky adducts (Harfe and Jinks-
Robertson, 2000).  MMR is conserved from bacteria to humans, albeit there are important 
differences among organisms.  Mutations in MMR genes predispose individual to 
hereditary non-polyposis colon cancer (HNPCC) syndrome (Jiricny and Nystrom-Lahti, 
2000; Aquilina and Bignami, 2001; Fishel, 2001; Peltomaki, 2001). Patients with 
HNPCC show loss of heterozygosity at MMR loci or promoter silencing of hMLH1 gene 
(Herman et al., 1998) and exhibit microsatellite instability (MSI).  Unlike other repair 
pathways, MMR is unique in recognition of parental strand and daughter strand, although 
significant part of the repair mechanism is similar to NER.  Firstly, the hMSH2-hMSH6 
heterodimer bound to the miusnmatch lesion recruit hMutSα to unwind the DNA in ATP 
dependent manner. This is followed by the recruitment of the hMutLα complex 
(hMLH1/PMS2) and PCNA leads to form a loop structure with the MMR proteins at the 
mismatched base reside in the loop. The subsequent steps involve degradation of the 
error-containing strand by exonucleases, HEX1 (human homologue of EXO1) followed 
by PCNA dependent repair synthesis. Due to its association with MSH2, MLH1 and 
PMS2, PCNA is probably the critical factor in recognition, DNA synthesis (Gu et al 
1998) as well as in strand discrimination during MMR. 
Interestingly, intact MMR function is required for the cytotoxicity of methylating drugs. 
In MGMT deficient cells, unrepaired 6meG will mispair with thymine (T) upon 
replication. This triggers the MMR directed to cleave the newly synthesized strand 
containing the T. Since O6-meG is not repaired, each DNA replication will generate a 
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futile cycle of excision and resynthesis results in strand breaks which lead to cell death.   
p53 dependent apoptosis where decrease in Bcl-2, hypophosphorylation of Bad, release 
of cytochrome c, and activation of the caspases 9 and 3 are observed (Ochs and Kaina, 
2000; Aquilina and Bignami, 2001).  Interestingly, MMR-dependent apoptosis can also 
be executed via p53-independent manner (Aquilina et al., 1998; Hickman and Samson, 
1999). Interestingly, the MMR system was recently shown to be involved in the 
processing of oxidative damage in mammalian cells (Colussi et al., 2002) and implicated 
in the control of S-phase checkpoint induced by ionizing radiation (Brown et al., 2003), 
suggesting cross-talks among DNA-damaged response pathways. 
 
1.2.4    Double Strand Breaks Repair (DSB) 
Double strand breaks (DSBs) induced by DNA damaging agents must be dealt with 
cautiously as it is similar to the 2 ends of the chromomsome, DSBs are also found in 
meiotic recombination and immunoglobulin gene rearrangements. Unrepaired DSBs will 
cause permanent cell cycle arrest, induction of apoptosis or mitotic catastrophy (Olive 
PL, 1998) and incorrectly repaired DSB will lead to translocations, inversions, or 
deletions  observed in tumour cells (Hoeijmakers, 2001; van Gent et al., 2001). 
DNA DSBs are repaired by homologous recombination (HR) or nonhomologous end-
joining (NHEJ)  (Bradbury and Jackson, 2003; Valerie and Povirk, 2003; West et al., 
2000).  The single-strand annealing (SSA) HR was identified in Xenopus laevis oocytes 
and mammalian cells (Jeong-Yu and Carroll, 1992; Lin et al., 1990; Maryon and Carroll, 
1991) which requires the presence of repeated sequences on both sides of the break and 
DNA deletion is introduced via this mode of repair. 
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Homologous recombination (HR) repair involves interaction between the broken DNA 
molecule and its intact sister chromatid and is mediated by proteins encoded by the RAD 
(radiation resistance) genes with error-free. HR functions at the G2/M phases of the cell 
cycle, where sister chromatid is available as a template for repair (Takata et al., 1998; 
Johnson and Jasin, 2000), whereas nonhomologous end-joining (NHEJ) is a simpler 
process rejoining the broken DNA ends involving no template and thus, error-prone as 
deletions of a few nucleotides are introduced at the site of DSB. NHEJ plays an important 
role in quiescent (G0) or G1 phase of the cell cycle (Khanna and Jackson, 2001) during 
which the sister chromatid is unavailable. Contrasting to HR, which is important for 
endogenous meiosis and interstrand crosslinks repair, NHEJ is crucial for 
immunoglobulin gene rearrangements and teleomere maintenance (Ferguson and Alt, 
2001).  The choice of HR or NHEJ to repair DSBs is dependent on the nature of the DNA 
ends at breakage site, status of the cell cycle, and balance between the levels of Ku and 
Rad52 proteins 
In NHEJ repair process, the subunit of Ku70/Ku80 heterodimer bind to the free ends  of 
DSB and recruit the DNA-protein kinase (DNA-PKcs) which phosphorylates a number of 
proteins, including itself and the Ku heterodimers (Gottlieb and Jackson, 1993; Kanaar et 
al., 1998; Ding et al., 2003).  The ends of the DNA are unwound and processed by the 
Rad50-Mre11-Nbs1 complex containing both helicase and exonuclease activities 
(Khanna and Jackson, 2001).  The ends are ligated by the XRCC4/DNA ligase IV 
complex.  Recently, an exonuclease, Artemis, was shown to play an important role in 
NHEJ pathway particularly in the V(D)J recombination and radiation repair (Moshous et 
al., 2001; Jeggo and O'Neill, 2002; Moshous et al., 2003).  
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HR repair involves multiple proteins. Firstly, cells harboring DSBs are arrested at G2/M 
through the activation of ATM (ataxia telangietasia mutated) kinase-mediated 
checkpoint.  These DSB ends are first recognized and bound by the Rad52 protein to 
recruit the Rad50-Mre11-Nbs1 complex, which generates a single-stranded region with 
3’-overhang where the Rad51 proteins polymerise to form the nucleoprotein filament. 
This process requires the coordinated action of single-stranded DNA-binding protein, 
replication protein A (RPA), Rad52, Rad51 paralogues, XRCC2, XRCC3, Rad51B,C, 
and D, BRCA1 and BRCA2 (Venkitaraman, 2002).  This nucleoprotein filament then 
searches for homologous duplex DNA (sister chromatid) for strand-exchange reaction 
catalyzed by Rad52 and Rad54 proteins to generate a joint molecule between the 
damaged and undamaged DNA. Subsequently, DNA synthesis takes place and Holliday 
junctions (crossed DNA strands) are formed. The Holliday junctions are resolved by 
accurate repair to yield two intact duplex DNAs  (Kanaar et al., 1998; van Gent et al., 
2001; West, 2003).    
Defective DSB repair is manifested by chromosomal instability as exhibited by ataxia-
telangiectasia (A-T, resulting from defects in ATM gene), AT-like disorder (ATLD, arise 
from Mre11 defects), Nijimegen breakage syndrome (NBS, resulting from defective 
NBS1) and Fanconi anemia (FA, resulting from defective FANCD2 protein) (Carney et 
al., 1998; Thompson and Schild, 2002). Furthermore, the breast-cancer-susceptibility 
genes, BRCA1 and BRCA2, which encode large multifunctional proteins may also 
involved as loss of their functions lead to the accumulation of spontaneous chromosome 
breakages, accompanied by checkpoint-mediated growth arrest, aneuploidy and 
centrosome amplification. This is probably aroused from their interaction with Rad51 (an 
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essential protein in homologous recombination repair) implicating their roles in breast 
cancer arising from defective HR (Venkitaraman, 2002).  
 
1.2.5   Direct Repair 
The bacterial Ada protein provides an excellent example of evolution where fusion of 
two related proteins into a ‘composite’ bifunctional protein. The Ada protein serves as an 
inducible regulator in E.coli to confer resistance to the methylating agents (Lindahl et al., 
1988). The N-terminal of Ada (N-Ada) confers phosphortriesterase transfer activity 
whereas the C-terminal (19kDa) directly demethylates the mutagenic base O6-meG and 
O4-meT lesions by its Cys321 residue as a methyl-acceptor (Demple et al., 1985). Both 
repair activities are ‘suicidal’. 
In yeast and bacteria, UV-induced pyrimidine dimers are reversed by photolyase (Sancar, 
2003), but not in higher eukaryotes (Todo et al., 1997).  However, the mechanism for 
direct reversal of alkylation damage is conserved from bacteria to human for the O6-
alkylguanine (6RG) lesions which are encoded by O6-methylguanine-DNA 
methyltransferase  (MGMT) (Zaidi et al., 1995) and human homologues of E.coli AlkB, 
ABH2 and ABH3 dioxygenases.  The lesions 1-methyladenine (1-meA) and 3-
methylcytosine (3-meC) will surface in single-stranded DNA (Bodell and Singer, 1979), 
in replication forks or in actively transcribing genes because they block DNA and RNA 
polymerases (Larson et al., 1985; Boiteux and Laval, 1982). They are the substrates for 
the ABH2 and ABH3 dioxygenase which catalyse the oxidative release of the methyl 
group as formaldehyde (Aas et al., 2003; Duncan et al., 2002; Falnes et al., 2002; 
Koivisto et al., 2003; Trewick et al., 2002). Surprisingly, Aas et al (Aas et al., 2003) 
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showed that both the bacterial AlkB and human equivalent hABH3 can also repair RNA.  
Alkylation damages to RNA should have deleterious consequences as this will lead to 
instant formation of mutated proteins that may cause improper cellular function. 
The direct reversal repair of the mutagenic O6-alkylguanine lesions by MGMT has been 
widely studied because of its role in resistance to antineoplastic agents, such as, BCNU 
(1,3-bis(2-chlorethyl)-1-nitrosourea)  and NMU (N-methyl-N-nitrosourea) (Wasserman, 
1976). Alkylating agents that form adducts at the O6 position of guanine in DNA are an 
important class of mutagens and carcinogens. For example, nitrosoureas are known to 
induce mutations –G to A transitions, arising from the lesion O6-methylguanine and G to 
T transversions after chloroethylation at the O6 position of guanine (Allay et al., 1999; 
Minnick et al., 1993; Pegg, 1984).  In vivo data from experimental animals suggested that 
these mutations lead to malignant transformation, resulting in colon, lung tumours and 
lymphomas (Dumenco et al., 1993; Lijinsky and Kovatch, 1989; Liu et al., 1999; Zaidi et 
al., 1995). 
The human MGMT gene is located on chromosome band 10q26, with five exons but only 
four of which are coding. Its promoter lacks TATA and CAAT boxes but contains SP1 
and AP-1 sites as well as a glucocorticoid response element (Pegg, 2000).  The human 
MGMT protein is about 21kDa in size. The expression of MGMT is highly variable in 
cultured cells and in mammalian tissues. There are cell lines that do not express MGMT 
and are termed as Mer- (methyl-excision repair) (Day, III et al., 1980), conversely, cell 
lines or tissues that express MGMT have been designated Mer+. So far,  about 60% of 
SV40 and Epstein-Barr virus transformed and some tumour-derived cell lines are Mer- 
(Green et al., 1990; Harris et al., 1996). Although it has been reported that expression of 
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MGMT in transgenic mice protected them against alkylating agents, there is no evidence 
that Mer- phenotype is related to tumour cells (Dumenco et al, 1993).  
The repair mechanism of MGMT based on current model, suggests that MGMT binds to 
DNA via a helix-turn-helix motif in its C-terminal domain. The repair mechanism 
involves the flipping out of the alkylated base into the active-site of MGMT. 
Subsequently, the alkyl group from O6-alkylguaine in DNA is covalently transferred to a 
cysteine acceptor located within the active-site –PCHRV- of MGMT. This cysteine 
acceptor, C145, is not regenerated upon repair and therefore, MGMT can only function 
once (Hansen and Kelley, 2000). This stoichiometric reaction results in “suicidal’ 
inactivation of the MGMT protein. The alkylated protein is subsequently detached from 













1.3 Nuclear Hormone Receptor 
1.3.1 The nuclear receptor superfamily 
In mammals, lipophilic ligands, such as estrogen, progesterone and androgens, retinoids 
and vitamin D3, regulate the gene expression at various stages of differentiation and 
morphogenesis by association with nuclear hormone receptors (NHR or NR) (Aranda and 
Pascual, 2001), which form a large superfamily of phylogenetically related proteins; 49 
human genes which have been definitively cloned and identified (Robinson-Rechavi et 
al., 2001; Robinson-Rechavi and Laudet, 2003), 21 genes from Drosophilia 
melanogaster  and 270 genes from nematode Caenorhabditis elegans  (Enmark and 
Gustafsson, 2001; Adams et al., 2000; Sluder and Maina, 2001). Based on alignment of 
the well-conserved DNA-binding domain (DBD) and ligand-binding domain (LBD), 
through phylogenetic analysis, this superfamily was classified into six subfamilies.  The 
thyroid hormone receptors (TRs), retinoic acid receptors (RARs), vitamin D receptors 
(VDRs) and peroxisome proliferator-activated receptors (PPARs) as well as other orphan 
receptors (such as retinoic-acid related orphan receptor, ROR) belong to the first family 
whereas the retinoid X receptors (RXRs), chicken ovalbumin upstream stimulators 
(COUPs), hepatocyte nuclear factor 4 (Stroup and Chiang, 2000) and receptor involved in 
the eye development (TLX and PNR) are from the second family. The third family 
consists of steroid receptors, such as estrogen receptor (ERs), glucocorticoid receptors 
(GRs), androgen receptors (ARs), progesterone receptors (PRs) and the orphan receptors 
estrogen-related receptors (ERRs).  In addition, the orphan receptors NGFI-B (NGF-
induced clone B), FTZ-F1 (Fushi Tarazu factor 1) and GCNF (germ cell nuclear factor) 
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are classified as three subfamilies respectively (Amero et al., 1992; Detera-Wadleigh and 
Fanning, 1994; Laudet, 1997; Aranda and Pascual, 2001).   
 
 
1.3.2 Structure/ domains of receptors 
All of the nuclear steroid receptors have common structural features which consist of six  








The N-terminal A/B domain, less conserved among the nuclear receptors, contains an 
active transactivation domain AF-1 with variable size and multiple isoforms generated by 
alternative splicing and/or alternative promoter usage of a single gene (Chambon, 1994; 
Kastner et al., 1990; Sartorius et al., 1993). AF-1 domain contributes the transcriptional 
activity of the receptor, targeting gene specificity of different receptors (Tsai and 
O'Malley, 1994; Warnmark et al., 2003). AF-1 can also be potentiated independent of 
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Fig 1.1  Schematic representation of nuclear receptor functional domains. 
The six functional domains (A to F) of nuclear receptors comprise of two major 
transactivation functions, AF-1 (A/B domain) and AF-2 (E domain), a DNA-
binding domain (DBD, C domain), a less conserved region (D domain) that acts 
as a flexible hinge between C and E domain. The largest E domain contains the 
ligand-binding domain (LBD) as well as dimerization surfaces. The F domain 
located at the extreme C-terminal of the receptor has a highly variable sequences 
and whose function is unknown. 
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ligand binding through phosphorylation of specific serine residues by mitogen-activated 
protein kinase (MAPK) following growth factors stimulation (Kato et al., 1995). Recent 
evidence suggests that AF-1 also interacts with certain transcription co-activators (Glass 
and Rosenfeld, 2000; McKenna et al., 1999; Webb et al., 1998).  
The conserved C region, which contains the DNA-binding domain (DBD), confers 
recognition specificity towards target gene sequences (or responsive elements) has two  
highly conserved zinc-fingers –C-X2-C-X13-C-X2-C and C-X5-C-X9-C-X2-C- motifs 
where the Xn residues (Lin et al., 1994a) in the first motif make contact with the central 
base pairs of the response element for specificity (Fairall et al., 1993; Schwabe et al., 
1993). Residues on the second finger  (‘D box’) are for dimerization.   
Located between the DBD and the ligand-binding domain (LBD) is the D domain (less 
conserved among the receptors), which serves as a flexible hinge between the C and E 
domains, contains the nuclear localization signal (NLS) and may be involved in steroid-
mediated transcriptional repression activity (Adler et al., 1988).   
The ligand-binding domain (LBD, E region) is a globular domain responsible for many 
functions. It harbors a ligand/hormone-binding pocket, sites for co-factor binding, 
receptor homo-or heterodimerization, a second hormone-induced activation function 
domain (AF-2), nuclear localization signal and interactions with heat shock proteins (Hsp 
90). The LBDs of different receptor have been crystallized (Moras and Gronemeyer, 
1998) which showed that the overall structures of different receptors are similar, despite 
the low primary sequence identity. The LBDs contain 12 α- helices (numbered H1-H12), 
and one β−turn arranged as an antiparallel α-helical sandwich in three layer structure, 
with a ligand binding cavity formed within the core of the LBD (Bourguet et al., 2000).  
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The liganded (holo) structures are more compact than the unliganded (apo) structures, 
demonstrating that binding of ligand induces a conformational rearrangement in this LBD 
domain. This agonist/ligand-induced conformational change generates a surface to which 
the nuclear-receptor interacting domain (NID) of co-activators binds (Fig 1.2) (Fu et al., 
2003; Bourguet et al., 2000; Fu et al., 2003; Glass and Rosenfeld, 2000; Robinson-
Rechavi et al., 2003). The last F domain at the extreme C-terminal region is highly 
variable with an unknown function and is absent in progesterone receptor (PR) and 
















Fig 1.2 Schematic drawing of three different conformational states of 
nuclear receptor ligand-binding domains (LBDs). (a)The unliganded (apo)
retinoid X receptor (RXR) LBD. (b) The agonist-bound (holo) retinoic acid 
receptor (RAR) LBD. (c) The antagonist-bound RAR LBD. The α-helices 
(H1–H12) are depicted as rods whereas broad arrows represent the β-turn. 
The various regions of the LBD are coloured depending on their function: the
dimerization surface is shown in green, the co-activator and co-repressor 
binding site, which also encompasses the nuclear receptor LBD signature 
motif6, is shown in orange and the activation helix H12 that harbours the 
residues of the core activation function 2 (AF-2) activation domain (AD) is 
shown in red; other structural elements are shown in mauve. Abbreviation: 
LBP,ligand-binding pocket. (Adapted from Bourguet et al., 2000)
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The conception of hormone NRs function as sequence-specific DNA-binding 
transcription factors was corroborated from the identification of the hormone response 
element (HRE) for glucocorticoid receptor (GR) (von der Ahe et al., 1985) which 
revealed a consensus 6 bp (basepair) half-site sequence constitute the core NR 
recognition motif: 5’-AGAACA-3’ and 5’-AGGTCA-3’. Characteristically, NRs can 
bind to HRE as a monomer or a dimer. However, most NRs bind as homo- or 
heterodimers to HREs composed of two core 6bp motifs separated by variable length 
nucleotide spacers. These dimeric HREs have various orientations such as direct repeat 
(DR), inverted repeats (IR) or palindromes (Pal) and everted repeats (ER) or inverted 













Fig 1.3 The interaction of receptors to hormone response elements (HREs).
Many of the NR bind as mono, homo- or heterodimers to their HREs. The core consensus 
motif of the HREs can be configured as palindromes (Pal), direct repeats (DR), or inverted 
palindromes (IP). (Adapted from Aranda and Pascual, 2001)
 
 
Structural and molecular studies of NR DBDs-HRE complex showed that residues in the 
receptor P box  (ie., the first zinc finger) confer specificity towards the half-site 
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recognition where the five residues in the P box make base-pair contact within the major 
groove of the HRE (Glass, 1994; Zilliacus et al., 1995).  The D box in DBD of NRs, 
contribute to DBD HRE recognition by detecting the spacing between the half-sites as 
well as dimerization (Dahlman-Wright et al., 1993; Perlmann et al., 1993; Umesono and 
Evans, 1989).   
 
1.3.3 Receptor  classifications  
The nuclear receptors can be classified into four categories based on their DNA-binding 
and dimerization properties (Fig 1.4) (Mangelsdorf et al., 1995).  In general, Class I 
receptors are steroid receptors such as GRs, progesterone receptor (PRs), androgen 
receptor (ARs) and mineralocorticoid receptor (MRs) which functions as homodimers 
binding to HREs with inverted repeats of 2 half-sites separated by 3 basepairs (IR-3s), 
but estrogen receptors (ERs), function as homodimers as well as heterodimers (Cowley et 
al., 1997; Tremblay et al., 1999). Class II receptors require heterodimerization with RXR 
family members and they bind to half-site direct repeats (DRs), separated by 1 to 5 bps 
(DR-1 to DR-5) (Mangelsdorf and Evans, 1995) which may define the identity of the 
dimerization partner.  Class III receptors are orphan nuclear receptors with no known 
ligands that bind to DRs as homodimers.  Lastly, Class IV receptors are orphan receptors 
bind to extended half-site sequences as monomers (Cairns et al., 1996; Chen et al., 1994; 






1.3.4 Transcriptional coregulators of NRs 
NRs functions in three steps: repression, de-repression and activation of transcription.  
Apo- or unliganded NR functions as repressor in complex possesses histone deacetylase 
(HDAC) activity. Upon ligand binding, holo-NR dissociates from the HDAC containing 
complex and recruits a co-activator complex containing histone acetyltransferase (HAT) 
activity to decondense chromatin for activation. This is followed by the dissociation of 
the HAT complex and recruitment of (TRAP/ARC/DRIP) for direct contact with the 
basal transcription machinery to transcribe the target gene (Metivier et al., 2003).  
The NR co-activators were identified through the observation of transcription 
interference or squelching.  When overexpression of one receptor suppress the function 
of  another receptor, suggesting competition among NRs for essential common co-factors 
(Meyer et al., 1989). Receptor interacting co-regulators were classified as co-activators 
when functions as ligand bound NR on HRE which lead to transcription activation or co-
repressors for unbound NR, where transcription of HRE is suppressed (Chen and Evans, 
1995; Fondell et al., 1996; Fu et al., 2003; Horlein et al., 1995; Khan and Nawaz, 2003; 
McKenna and O'Malley, 2002a; McKenna and O'Malley, 2002b; Rachez et al., 1998).  
NR interacting co-activator proteins include p160/SRC, p300/CBP, members of the 
TRAP/DRIP complex, the ubiquitin ligase E6-AP, the ATP-coupled chromatin 
remodeling SWI/SNF complexes, PCAF/GCN5 and TRAP/DRIP/ARC complexes; and 
co-repressors, including NCoR and SMRT (McKenna and O'Malley, 2002a; Rosenfeld 
and Glass, 2001; Stallcup et al., 2003). In general, co-activators are associated with HAT 
activities whereas co-repressors complex exhibit HDAC activities. 
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1.3.4.1  Nuclear receptor co-activators 
The p160 family of steroid receptor co-activator (SRC) proteins is best studied for their 
roles in activating ligand bound NR transcription. The SRC family consists of three 
homologous members (Xu and Li, 2003). Firstly, SRC-1/NCoA-1, which interacts with 
hormone receptors (ER, PR and TR and GR), as well as coactivates other transcription 
factors such as AP-1, serum response element and NF-κB (Fu et al., 2003; Xu and 
O'Malley, 2002). Secondly, SRC-2 (GRIP1/ TIF2/NCoA2) was identified through its 
interactions with LBD of GR and ER. Thirdly, SRC3 (p/CIP, RAC3, acetyltransferase 
ACTR, AIB1 or TRAM-1), which was found amplified in breast tumours, suggesting a 
link between breast cancer and coactivator misexpression.  The SRC coactivators share a 
common domain structure, with a highly conserved N-terminal (containing the basic 
helix-loop-helix motif, the PER/ARNT/SIM (PAS) domain and nuclear localization 
signal), a centrally located receptor interacting domain (RID) and two activation domains 
(AD1 and AD2) at the C-terminal. Detailed analysis of the RID led to the discovery of 
three conserved amino acid sequences called the LXXLL signature motif (in which L 






Fig.1.5 General structure of the SRC/p160 family. bHLH, basic helix-loop-
helix motif; PAS, Per/ARNT/SIM homologous; S/T, serine/threonine-rich 
regions; NR box, NR interaction domain; CBP/p300, CBP/p300 interaction 
domain; Q, polyglutamine stretch; HAT, histone acetyltransferase domains 
identified in SRC-1 and SRC-3; AD1 and 2, transcriptional activation domains. 
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This NR box is necessary and sufficient for interaction with the liganded receptor LBD. 
The structure of ER LBD complexed to fragments of the coactivator NR box showing 
that the LXXLL motifs form short α-helices that interacts a hydrophobic cleft in the 
LBDs of homo- or hetero- NR dimers (Shiau et al., 1998). Distinct LXXLL motifs and 
contextual sequences exhibit differential binding affinity for different NRs, suggesting 
NRs have a preference for one LXXLL motif over another in a coactivator or for one 
coactivator molecule over another (Leo and Chen, 2000). The AD1 region located at the 
C-terminal is responsible for interaction with general transcriptional cointegrators, CBP 
and p300. Although, AD1 has LXXLL-like motif, it does not bind NRs, and mutations in 
these motifs impairs the interaction of SRCs with CBP and p300 and the activation 
function of SRCs, indicating that AD1 is crucial for recruitment of acetyltransferases 
CBP/p300 and PCAF for chromatin remodeling at the site of receptor-directed 
transcriptional initiations.  Histone methyltransfrases such as coactivator –associated 
arginine methyltransferase 1 (CARM1) and PRMT1 can interact with the AD2 domain at 
its C-terminal (Chen et al., 1999; Koh et al., 2001).   
 
1.3.4.2    Co-integrators for NR-dependent transactivation 
Cointegrators such as p300/CBP act as bridges between the DNA-bound transcription 
factors and the general transcription factors (GTFs) by providing a scaffold for assembly 
of transcriptional machinery. They possess HAT activity and can recruit pCAF 
(p300/CBP-associated factor) (Giordano and Avantaggiati, 1999). Biochemical analysis 
showed that CBP preferentially interacts with SRC-3 over SRC1 and SRC2 (Torchia et 
al., 1997) by binding to the C-terminal of SRC family members. p300/CBP contains 
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other functional domains, such as CREB interacting domain (KIX) , three zinc finger 
domains (CH1, CH2 and CH3) and a bromodomain (involved in acetylated histones 
interaction) is present between the KIX and the second zinc finger. HAT activities are 
located between the bromodomain and the third zinc finger. SRC interacts at a SID (SRC 
interacting domain for binding SRC) domain and PCAF interacts at the CH3 domain. 
Interestingly, p300 was recently shown to contain a E4 ubiquitin ligase activity for p53 
tumour suppressor protein (Grossman et al., 2003). In addition, cointegrators can 
acetylate other non-histone proteins such as transcription factors to regulate their 
function. NR including ER, AR and ACTR were subjected to acetylation. For example, 
acetylation of ER in the hinge region resulted in transcriptional attenuation, whereas 
acetylation of AR promotes transactivation (Fu et al., 2000; Wang et al., 2001).  SRC 
coactivators can interact either directly or indirectly with pCAF, which is a mammalian 
homologue of yeast GCN5 with strong HAT activity. PCAF acetylates histones H3 and 
H4 for chromatin remodeling for transcription activation.  
Other coactivator complexes such as TRAP/DRIP/ARC complex are well studied. The 
TR-associated protein (TRAP) and the vitamin D receptor-interacting protein (DRIP) 
were cloned based on their interactions with activated TR and VDR (Fondell et al., 1996; 
Rachez et al., 1998). The TRAP/DRIP/ARC complex composed of more than a dozen 
subunits of size ranging from 70-230kDa. The complex is recruited to core AF-2 of NR 
via a single subunit (TRAP220/DRIP 205), which contains two alternatively utilized 
LXXLL motifs. This subunit then recruits the remaining preformed protein complex.  
Several of the TRAP/DRIP/ARC are homologues of the yeast Mediator complex, which 
associates with the large subunit of RNA polymerase II. This indicates that the 
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TRAP/DRIP/ARC potentially recruit RNA polymerase II to the target promoter (Naar et 
al., 1999).   
Transcriptional activation of NR mediated genes therefore involves binding of the NR to  
HRE where the coactivator/cointegrator proteins assemble to remodel the chromatin for 
transcription by RNA polymerase II. Each component accomplished a specific set of task 
and contributes to the overall specificity of NR-mediated target gene transcription 
activation. 
 
1.3.4.3 Nuclear receptor corepressor 
Corepressors are protein associated with unliganded or antagonist-bound nuclear 
receptors that mediate transcriptional repression (Robyr et al., 2000). The best 
characterized corepressors are the 270kDa nuclear receptor corepressor (Colussi et al., 
2002), and 168kDa silencing mediator for retinoid and thyroid hormone receptor 
(SMRT) proteins (Chen and Evans, 1995; Horlein et al., 1995).  NCoR/SMRT do not 
interact with unliganded NRs but they interact with agonist bound NR, such as 
tamoxifen-bound ERα.  These repressors harbour multiple domains that interact with 
Sin3A and histone deacetylases (HDACs) to mediate transcriptional repression by 
condensing the chromatin (Alland et al., 1997; Heinzel et al., 1997; Nagy et al., 1997). 
NCoR and SMRT are components of several corepressor complexes (Guenther et al., 
2000; Li et al., 2000; Underhill et al., 2000; Wen et al., 2000), which exhibit promoter 
and  cell type-specificity.  They interact with the hinge region of NRs via their C-terminal 
domain. A bipartite receptor-interacting domain (RID) at its C-terminal region which 
contains 17-19 amino acids domains with a consensus sequence of LXXXIXXXI/L, named 
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CoRNR box (Hu and Lazar, 1999; Nagy et al., 1999; Perissi et al., 1999). Biochemical 
analysis revealed that CoRNR box and the LXXLL motif in co-activators utilize the same 
NR surfaces for interactions. However, the extended helical CoRNR motif prevented it 
from binding to the ligand-bound NR unlike the shorter LXXLL helix that interacts with 
liganded NR through charge-clamp mechanism. The extended helix of CoRNR motif 
displaces the AF-2 helix of NR out of the pocket and makes contact with the coactivator-
binding pocket. The CoRNR motif is therefore crucial for distinguishing ligand-
independent binding of corepressors and ligand-dependent recruitment of coactivators to 
the NR (Perissi et al., 1999). 
 
1.3.4.4 The chromatin link 
Eukaryotic DNA is highly organized into chromatin, with repeats of a protein-DNA 
complex consists of nucleosome wrapped by 146bp of DNA, this impedes transcription. 
Acetylation of the histones H3 and H4 can generate an open chromatin conformation and 
allows binding of transcription factors to the promoter region of genes (Struhl, 1998; 
Wolffe and Pruss, 1996). Hence, hyperacetylated chromatin is often associated with 
transcriptionally active genes, while silent ones are usually hypoacetylated. The levels of 
histone acetylation are regulated by two opposite enzymatic activities, histone 
acetylatransferases (Chen et al., 2001) and histone deacetylases (HDACs), which are 
found in coactivators and corepressors respectively.  Upon ligand activation, p160 family 
proteins such as SRC-1 are recruited to the ligand bound NR and serve as platform to 
recruit the cointegrator p300/CBP to remodel the chromosomal structures via their HAT 
activities. This allows the TRAP/DRIP complex to enter and interact with the liganded 
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NR. Subsequent recruitment of the RNA polII complex to TRAP/DRIP completes the 
transactivation process.  On the other hand, in the absence of ligand, the NRs, are 
repressed by binding of co-repressors such as, NCoR and SMRT, mSin3A which possess 
HDACs activities. This will condense the region of the DNA to prevent binding by 
transcription factors. In conclusion, transcriptional regulation of NR is mediated through 
ligand-dependent dissociation of HDAC-containing corepressor complexes and 
association of HAT activities containing coactivator complexes. 
 
1.3.5 Function and regulation of Estrogen receptor  
Breast cancer is a major disease in woman worldwide and epidermological studies have 
indicated the role of estrogen receptor (ERα) in this disease. Estrogen or synthetic 
estradiol (Scheffner et al., 1995b) is important in the development of female breast tissue 
(Korach, 1994) and homeostasis of other tissues through activation of the estrogen 
receptors (ERs). ERα and ERβ are two isoforms of ERs identified (Green et al., 1986; 
Kuiper et al., 1996; Mosselman et al., 1996) and they  belong to the nuclear receptor 
superfamily. Although ERβ is expressed in many tissues as compared to ERα, its normal 
function and potential role in cancer progression is uncertain. ERα and ERβ differ mostly 
in the N-terminal A/B domain and to a lesser extend the ligand-binding domain, LBD, (E 
domain) which may explain the difference in response to estrogens or antagonists (such 
as tamoxifen and raloxifene) (Barkhem et al., 1998). The C or DNA-binding domains of 
ERα and ERβ are highly homologous (Enmark et al., 1997) with identical P box 
sequences, thus they are able to bind to different various estrogen response elements 
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Structural analysis of the LBDs of these two receptors with estradiol and antagonist 
raloxifene revealed major conformation change in the AF2 domain resided in the LBD.   
Four different pathways can mediate the biological effects of estrogen: 1) classical 
ligand-dependent; 2) ligand-independent, 3) DNA-binding-independent; 4) nongenomic 
signaling (Hall and Korach, 2003; McDonnell, 2003). In the classical mechanism of 
estrogen response, the unliganded ERα and ERβ receptors forms an inactive complex 
with Hsp90 (Nicholson et al., 1999). Upon ligand binding and dissociation from Hsp90, 
the receptors are activated. The liganded bound receptor adopts a conformation change 
and facilitates the dimerization of receptors.  The receptor dimer binds with high affinity 
to specific DNA response elements (e.g. EREs), usually located at the enhancer region of 
target gene. This activated complex contacts the GTFs either directly or indirectly via 
coactivators, such as SRCs (Rosenfeld and Glass, 2001). Recruitment of these cofactors 
aids in chromosomal remodeling at the ERE and bring about transcriptional activation of 
the target gene. Targets of the classical estrogen signaling include many genes involve in 
cell cycle and cellular proliferation, such as, cyclin D1, c-fos, c-jun, c-myc and c-myb 
Fig. 1.6 Structural comparison between hERα and hERβ 
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(Altucci et al., 1996; Loose-Mitchell et al., 1988; May and Westley, 1995; Weisz and 
Bresciani, 1993). However, some genes are down regulated by estrogen treatment, 
perhaps through competition between different nuclear receptors and co-activators. These 
include p21WAF1, p27Kip1 and TGFβ (Foster et al., 2001; May and Westley, 1995). 
Recently, a hormone-independent binding of SRCs to the ER was observed (Zwijsen et 
al., 1997; Zwijsen et al., 1998) where association of between leucine rich region at C-
terminal of cyclin D and ER allows SRCs to interact with the complex and results in 
transactivation.  In this case, cyclin D1 can also synergistically activate ligand bound ER.  
Extracellular signals from growth factors such as EGF (epidermal growth factor) and 
IGF1 (insulin-like growth factor-1) can activate ER (Smith, 1998) in an ligand-
independent manner. These growth factors activate ER through the N-terminal AF-1 
domain as compared to cyclic AMP (cAMP) modulation of ER which activates through 
the AF-2 domain (El Tanani and Green, 1997). Furthermore, phosphorylation of serine 
118 in the AF-1by the MAPK kinase pathway upon treatment with IGF and EGF also 
activates the ER activity.  In addition, phosphorylation of ER coactivators such as SRC1 
and AIB1 by MAPK also activate ER (Font and Brown, 2000; Osborne et al., 2001; 
Rowan et al., 2000).  
Interestingly, in IGF1 activation, ER activity is mediated through the binding of AF-1 
and AF-2 domains of ER to the AP-1 site of Fos and Jun to recruit coactivator complex 
by Fos and Jun (Kushner et al., 2000). Lastly, it was suggested that estrogens could elicit 
non-genomic pathways where subpopulation of ER may reside at the plasma membrane 
or caveolae to facilitate rapid actions of estrogens that do not involve transcription 
(Chambliss et al., 2002; Norfleet et al., 1999).  
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ERα is subjected to negative regulation by ERβ. In cells with both receptors, ERß 
exhibits an inhibitory action on ERα-mediated gene expression due to the competition 
between the 2 NRs for the limited co-activators(Hall and McDonnell, 1999; Weihua et 
al., 2000). This is similar to  progesterone receptor (PR-A) in modulating the ERα 
transcriptional activities (Mulac-Jericevic et al., 2000; Wen et al., 1994). ERα-mediated 
transcriptional activity can be regulated by receptor acetylation (Wang et al., 2001) 
because the hinge region of ERα contains an acetylation motif RSKK similar to the p53 
acetylation motif. Acetylation of ERα attenuates ligand-dependent transactivation of 
target gene.  In fact, mutation in the acetylation site, ERαK303R, which showed 
enhanced ligand sensitivity is a common mutation found in atypical breast hyperplasias. 
This mutation also results in increased cellular proliferation at low level of estrogens 
(Fuqua et al., 2000), suggesting that mutation at acetylating site might contribute to 
breast cancer. 
ERα has been shown to interact with the amino terminal of p53 protein and protect p53 
from degradation by MDM2 (Liu et al., 2000; Yu et al., 1997). p53/ERα may be a 
negative regulator of each other since ERα activates cell proliferation and p53 blocks cell 
cycle progression.  Furthermore, MDM2 was shown to physically interact with ERα at its 
AF-2 domain, leading to increased level of estrogen dependent transcription (Saji et al., 
2001). Elevated expression of MDM2 has been observed in majority of ER positive 
breast cancer at the protein and the mRNA level, and its expression is up regulated by 
estrogen. (Bueso-Ramos et al., 1996; Gudas et al., 1995; Hori et al., 2002; Marchetti et 
al., 1995; Risinger et al., 1994; Sheikh et al., 1993).  Given MDM2 is a negative factor 
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for p53, overexpression of MDM2 may be a potential mechanism leading to neoplastic 






















1.4 The MDM2/p53 pathway 
1.4.1 MDM2 is oncogenic 
The MDM2 gene was initially identified on double-minute chromosomes of the mouse 
tumorigenic cell line 3T3DM (Fakharzadeh et al., 1991). Cell lines that overexpress 
MDM2 can form tumours in nude mice, although they do not have the ability to grow in 
soft agar or form foci (Fakharzadeh et al., 1991).  It can also mediate immortalization and 
transformation of rat embryonic fibroblasts in cooperation with the activated ras gene 
(Finlay, 1993). The human homologue, HDM2 was also amplified in a large proportion 
of human sarcomas and leukaemias, breast carcinomas and other types of cancer 
(Cordon-Cardo et al., 1994; McCann et al., 1995; Oliner et al., 1992; Quesnel et al., 
1994; Bueso-Ramos et al., 1993; Bueso-Ramos et al., 1996). In addition, normal tissues 
of the cancer-prone Li-Fraumeni family was found to overexpress MDM2, and the 
overexpression is p53-independent (Picksley et al., 1996). Furthermore, mice with 
targeted overexpression of MDM2 developed mammary gland tumours (Lundgren et al., 
1997). With the above observations, MDM2 is classified as an oncogene. 
 
1.4.2. Stucture of MDM2 
The human mdm2 (hdm2) gene is located on chromosome 12q13-14. It consists of 12 
exons to give a message of 1526bp long. It has two promoters, P1 and P2, leading to 
initiate translation at different AUG (Barak et al., 1994; Bartel et al., 2002; Matsumoto et 
al., 1998; Zauberman et al., 1995). Transcriptions from constitutive P1 lack exon 2 and 
transcripts arise from p53-sensitive P2 lack exon 1. The proteins derived from these two 
mRNAs are similar as translation begins in exon 3. The full-length transcript encodes a 
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protein of 491 amino acids. However, as many as 40 different splice variants of mdm2 
have been documented (Bartel et al., 2002), many of which arise from the use of 
alternative internal splice sites. The functions of these different forms of MDM2 are 






Alignment of the mdm2 proteins from different organisms highlighted 3 well-conserved 
regions, dubbed CR1, CR2 and CR3 (Momand et al., 2000; Piette et al., 1997). CR1 
(residues 42-94) is responsible for p53, p73, E2F1 and DP1 binding.  CR2 (residues 301-
329) contains a zinc-finger domain overlapping the Retinoblastoma (Rb) tumour 
Fig 1.7 Structure of mdm2 gene and protein. Two promoters are found in the gene and 
p53 binding site is located in intron1. MDM2 full-length protein is 491aa long, and the 
domains and the various proteins binding sites are indicated. NLS: nuclear localization 
signal; NES: nuclear export signal; ID1, ID2: growth inhibitory domains 1 and 2; NoLS: 
nucleolar localization signal; Zn finger: zinc-finger domain; RING finger: ring-finger 
domain. 
 36
suppressor protein-binding site. CR3 (residues 444-483) encodes the RING-finger 
domain which are frequently found in proteins with the property of a ubiquitin-ligase E3 
activities or part of the E3 complex (Glickman and Ciechanover, 2002; Weissman, 2001). 
E3 are responsible for substrate recognition in the ubiquitin-dependent-proteolytic 
pathway where a ubiquitin-protein adduct is formed by three sequential steps (Glickman 
and Ciechanover, 2002; Weissman, 2001) involving the ubiquitin-activating enzyme 
(E1), the ubiquitin- conjungating enzyme (Scheffner et al., 1995) and the ubiquitin ligase 
(E3). E1 is a common enzyme in all ubiquitination reactions, while the E2 and E3 vary 
dependent on substrate. The resultant ubiquitinated proteins are degraded by the 
proteosome  (Huibregtse et al., 1995; Scheffner et al., 1995). RING finger of mdm2 plays 
a crucial role in regulating p53 protein stability. At present, there is no mdm2 homologue 
in Drosophila melanogaster, Saccharomyces cerevisiae or Escherichia coli.  
 
1.4.3 The tumour suppressor p53 
The p53 tumour suppressor protein was first discovered in 1979 through its interactions 
with transforming large T-antigen of DNA tumour viruses, SV40 (Linzer and Levine, 
1979; Lane and Crawford, 1979; Levine, 1997; Vogelstein et al., 2000). Since then, p53 
has ‘transformed’ from a potential oncogene to a principal tumour suppressor in 
mammals.  It is widely accepted that inactivation of p53 is a precondition to most 
cancers; as shown in animal models where p53-null mice are prone to cancer 
(Donehower et al., 1992; Jacks et al., 1994). Mutations or loss of p53 are found in 50% 
of common tumour from colon, lung, liver and breast (Beroud and Soussi, 1998; 
Hollstein et al., 1991; Hainaut and Hollstein, 2000). Besides the gene mutations, 
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functional inactivation of wild-type p53 by disruption of the pathways regulating p53 
function can also lead to malignancy. p53 was shown to be a potent transcription factor 
that binds to promoter of genes induced upon exposure to different DNA damaging 
agents (Kastan et al., 1991; Haffner and Oren, 1995; Kern et al., 1991). These include   
p21WAF1, GADD45, BAX, MDM2, Reprimo and many others (el Deiry, 1998; Zhao et 
al., 2000). These genes inhibit the cell-cycle progression from G1-to S- phase or the G2- 
to mitosis phase, to provide window for cell to repair DNA damages. The ability of p53 
to induce G1-arrest upon is through transactivation of p21WAF  (el Deiry et al., 1993; 
Xiong et al., 1993), which inactivates the CDKs/cyclin coupled through their direct 
inactivation. On the other hand, p53 regulates G2/M checkpoint through the induction of 
14-3-3 sigma (σ) protein which sequester the cyclinB1-CDK1 (Hermeking et al., 1997; 
Chan et al., 1999; Laronga et al., 2000). A newest identified p53 target gene, Reprimo, 
can also arrest cells in G2 phase (Ohki et al., 2000). In addition, p53 is involved in 
apoptosis by activating genes including Bax, DR5 p53AIP1, NOXA, PUMA and other 
redox related genes to remove the damaged cells through apoptosis (Vousden, 2000). The 
exact mechanisms by which a cell decides between cell-cycle arrest or apoptosis remains 
to be elucidated.   Aberrant regulation of p53 can be disastrous as it causes organ atrophy 
(Mendrysa et al., 2003) or embryonic lethality (Jones et al., 1995b; Montes de Oca et al., 
1995). Therefore, p53 is tightly regulated by MDM2 oncoprotein which targets p53 for 
nuclear export and proteosomal degradation as well as a series of post-translational 





1.4.4 MDM2 –p53 autoregulatory feedback pathway 
1.4.4.1. MDM2 blocks p53 transcriptional activity 
In response to DNA damage, which leads to an increase in p53 (Livingstone et al., 1992), 
p53 activates expression of the MDM2 gene (Wu et al., 1993). The MDM2 protein 
produced interacts with p53 and inhibits its function (Juven-Gershon and Oren, 1999; 
Momand et al., 1992; Momand et al., 2000). The N-terminal of MDM2 (residues 19-102) 
binds to p53 was mapped to a 15-residue peptide of p53. Structure of this complex show 
the peptide has an amphipathic alpha helical structure (Chen et al., 1993; Oliner et al., 
1993) that binds to the hydrophobic cleft of MDM2, through  the critical residues F19, 
L22 and W23 (Picksley et al., 1994; Lin et al., 1994b; Kussie et al., 1996). 
Phosphorylation of the T18 residue (but not S15 and S20) (Kussie et al., 1996), abrogates 
the p53-MDM2 interaction (Schon et al., 2002). Since residues L22 and W23 are 
required for the transcriptional activity of p53 or binding to TAF31, and they are masked 
in the complex, MDM2 therefore inhibits the activation of p53-responsive genes. Since 
MDM2 is a product of p53 transactivation function, up-regulation of MDM2 protein 
provides a negative feedback loop for p53 activity.  
 
1.4.4.2. MDM2 role as ubiquitin E3 ligase  
The regulation of p53 by MDM2 is crucial for survival. Animal studies showed that 
homozygous deletion of MDM2 gene in mice results in early embryonic lethality, but this  
can be rescued by additional homozygous deletion of the p53 gene (Jones et al., 1995; 
Montes de Oca et al., 1995). More importantly, overexpression of MDM2 results in 
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lower levels of p53 (Kubbutat et al., 1997; Haupt et al., 1997) because MDM2 
ubiquitinates p53 via its E3 ligase activity and targets p53 for degradation (Maki et al., 
1996; Honda et al., 1997).  MDM2 belongs to the family of RING finger ubiquitin ligases 
(Jackson et al., 2000), which mediate self-ubiquitination as well as ubiquitination of other 
substrates.  p53 ubiquitination requires both its C-terminal lysine residues and the 
oligomerization domain (Kubbutat et al., 1998; Rodriguez et al., 2000; Maki, 1999). A 
recent study suggests that MDM2 mediates multiple monoubiquitin attachment to p53 
(Lai et al., 2001) while p300 mediates subsequent polyubiquitination, via its E4-like 
enzyme activity (Grossman et al., 2003).  Autoubiquination sites in MDM2 have not been 
identified. It was widely accepted that ubiquitination of p53 by MDM2 is essential for 
degradation and nuclear export of p53 for degradation in the cytoplasm. However, recent 
study (Li et al., 2003) demonstrated that in unstressed cells with low level of MDM2, 
monoubiquitination of p53 occurred and  p53 was cytoplasmic translocated. Conversely, 
when the levels of MDM2 increase, MDM2 mediates p53 polyubiquitination and induces 
p53 degradation in the nucleus.  
 
1.4.5 Regulation of MDM2-p53 loop 
In order for p53 to serve as a guardian of the genome, it must escape from MDM2 
inhibition to activate transcription when cells are exposed to DNA damaging agents. A 
critical role for p53 stabilization is via phosphorylation and acetylation. Phosphorylation 
at sites near or within the MDM2 interactions domain of p53 (i.e. S15, T18 and S20) 
disrupts their interactions. Phosphorylation of p53 is mediated by ataxia telangiectasia 
mutated (ATM) kinase or the checkpoint kinase-2 (Caspari, 2000; Shieh et al., 2000; 
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Banin et al., 1998). ATM phosphorylates p53 at S15 while CHK-2 prefers S20 and T18 
(Shieh et al., 1997; Shieh et al., 2000; Banin et al., 1998). However, S15 and S20 
phosphorylation did not affect the binding of the N-terminal peptide to MDM2 but T18 
phosphorylation reduced their interaction by 20-fold. Thus, T18 phosphorylation is 
crucial for disrupting the p53-MDM2 binding (Schon et al., 2002; Lai et al., 2001).  
Other mechanisms involve changing the MDM2 protein levels, such as UV radiation and 
hypoxia which reduce the levels of MDM2 and thus increase the p53 levels due to lower 
degradation by MDM2  (Wu et al., 1993; Wu and Levine, 1997; Rodriguez et al., 1999; 
Alarcon et al., 1999). In addition, UV damage facilitates sumoylation of p53 at K386, in 
turn enhances its transcriptional activity (Rodriguez et al., 1999).  
Conversely, modification of MDM2 directly by phosphorylation is important for p53 
stabilization. MDM2, which contains 20% of serine and threonine, are substrates for a 
number of kinases such as, AKT/PKB, cylinA-CDK1/2, c-ABL, DNA-PK and ATM.  
ATM can phosphorylate MDM2 at S395 and impairs the nuclear export of p53 for 
degradation (Khosravi et al., 1999; de Toledo et al., 2000; Maya et al., 2001). Activated 
AKT phosphorylates serine 166 and 186 in the nuclear localization motif of MDM2 and 
thus cause nuclear translocation of MDM2 from the cytoplasm to the nucleus and 
ubiquitinates p53 (Mayo and Donner, 2001; Zhou et al., 2001; Ashcroft et al., 2002; 
Gottlieb et al., 2002). However, this is countered by PTEN (phosphatase and tensin 
homologue deleted on chromosome 10), which is induced by p53. PTEN is able to block 
action of AKT, prevent nucleus localization of MDM2, leading to increase the cellular 
level of p53 (Mayo et al., 2002b; Mayo and Donner, 2002). 
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The best characterized phosphorylation independent stabilization of p53 is via tumour 
suppression p14ARF, the alternate product of INK4A/p16 locus (Mayo et al., 2002; 
Mayo and Donner, 2002; Kamijo et al., 1998; Honda and Yasuda, 1999; Zhang et al., 
1998; Quelle et al., 1995). Deregulated oncogenes, such as oncogenic Ras mutants, c-
myc and E2F1 (Bates et al., 1998; de Stanchina et al., 1998; Zindy et al., 1998; 
Pomerantz et al., 1998) stimulate the production of p14ARF which binds to MDM2 and 
inhibit its E3 ligase activity (Honda and Yasuda, 1999). p14ARF interacts at two sites on 
MDM2 (residues 154-221 and residues 271-342) (Pomerantz et al., 1998b; Zhang et al., 
1998) and sequester MDM2 into the nucleolus and thus prevent it from interacting with 
p53 (Tao and Levine, 1999; Weber et al., 1999). However, it is still unclear whether this 
sequestration of MDM2 takes place in nucleolus or nucleoplasm (Llanos et al., 2001). 
Regardless of how p14ARF inactivate MDM2, the end result is stabilization of p53.  
Other proteins, such as, MDMX, Rb and ribosomal protein L11, also affect the MDM2-
p53 regulatory cascade. MDMX is a RING finger structurally similar to MDM2, with 
conserved N-terminal p53-binding domain, a central acidic domain, zinc-binding motif 
and a C-terminal RING finger. MDMX can interact with p53 and MDM2, but lack the E3 
ligase activity (Tao and Levine, 1999; Weber et al., 1999; Shvarts et al., 1996; Finch et 
al., 2002; Gu et al., 2002; de Graaf et al., 2003; Linares et al., 2003). Genetic analysis 
showed that MDMX-knock out mice are viable only in a p53 null background (Parant et 
al., 2001) suggested that both MDM2 and MDMX are essential to control the growth-
suppressive properties of p53. Recent data showed that MDMX functions as a stimulator 
of MDM2 E3 ligase activity and hence enhance the rate of p53 turn-over (Linares et al., 
2003). Rb (Pomerantz et al., 1998) was shown to inhibit the degradation of p53 by direct 
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binding to MDM2 (Hsieh et al., 1999). Interestingly it does not interfere with the p53-
MDM2 interaction. However, the p53 protein in this p53/MDM2/Rb complex looses its 
transcriptional activity. Perhaps, this may be the mechanism where p53 is only partially 
activated to cause apoptosis but not cell cycle arrest.   
In conclusion, p53-MDM2 regulatory loop is subjected to regulation by myriads of 
proteins and different pathways in order to regulate p53 activities. Understanding these 
regulatory processes will be an added value to cancer diagnosis and therapy.  
 
1.5 Aims of research 
Upon exposure to different DNA damages, the cells respond by either going for cell cycle 
arrest in order to allow time for DNA repair or apoptosis, if the DNA damages are 
excessive. 
Human repair protein O6-methylguanine-methyltransferase (Zaidi et al., 1995) repairs 
O6- alkylation damages in DNA, by removing the alkyl groups, as well as larger adduct 
involving choroethylations, at the O6- position of guanine by covalent transfer 
mechanism. MGMT can also be inactivated via direct alkylation of its active site cysteine 
residue. These reactions irreversibly inactivate MGMT (generating active-site alkylated 
MGMT, R-MGMT). R-MGMT adopts a conformational change, which is characterized 
by sensitivity to protease V8 (Ayi et al., 1994). 
The aim of this study is to characterize the role of MGMT in regulating cell growth upon 
DNA damages as well as to define a role for this ‘suicidal’ repair mechanism by 
investigating the functions of the altered conformation of R-MGMT protein.  
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Chapter 2  Materials and Methods 
 
2.1 Cell Lines 
BT-474, BT-549, CEM, HCC-1500, HCC-1937, HeLaCCL2, Hs-578T, MCF7, 
MDA-MD-231, MRC5, NCI-H1299, T47-D and U2-Os were from the American 
Type Culture Collection (ATCC), MRC5.SV40 and ML1 were generous gifts from 
Dr. P. Karan (ICRF, UK) and Dr M. Kastan (St. Jude Children’s Research Hospital, 
USA) respectively. Cells were cultured using recommended medium with 10% FBS 
(Hyclone, USA) and antibiotics in incubator at 37oC with 5% CO2. 
 
2.2 Antibodies  
Polyclonal antibodies to MGMT (Pab.MGMT) and monoclonal antibodies Mab.5H7 
and Mab.2G1 were produced as described previously (Ayi et al., 1992, 1994). 
Mab.3C7 was purified from tissue culture supernatant of clone 3 (from a limiting-
dilution) using Protein-G Sepharose (Pharmacia). Mab.3C7 preferentially recognizes 
the active-site methylated recombinant human MGMT (Ayi et al., 1992) as compared 
to the native MGMT and GST-MGMT fusion protein in ELISA assays. 
Antibodies against p53 (DO-1), ERα (F-10), GR (E-20), BRCA-1 (I20), GFP (FL) 
were from Santa Cruz; antibodies against MDM2 (Ab-1 and Ab-2) and BRCA1 (Ab-
1) were from Oncogene; Antibodies against p14ARF and p21WAF1 were from 
NeoMarkers and Transduction Laboratories respectively and antibodies against Flag 
tag (Flag M2) from Sigma. 
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2.3 Drugs, Chemicals and other reagents 
O6-Benzylguanine (BG) is a gift from Dr. R. C. Moschel (NCI, Frederick, USA). 
NMU, ENU, DMS, DMSO, MeI (Sigma). Nuclear receptor ligands: 17-β-estradiol 
and dexamethasone (Sigma). FBS stripped of steroid by absorption to dextran-coated 
charcoal (cdex) (Hyclone,USA), phenol-red free cell culture medium (Gibco BRL), 
protease inhibitor cocktails (Sigma cat # P-8340). 
 
2.4 Epitope-Mapping of Mab.3C7 
The rat MGMT protein was from the first ssDNA affinity chromatography (Liem et 
al., 1994). The human MGMT  N- and C- terminus deletion mutants were produced 
as GST fusion proteins by cloning the PCR products, using BamH1-containing sense 
and EcoR1-containing antisense primers corresponding to 15 base residues in the 5’ 
and 3’ regions of the required inserts respectively (Ayi et al., 1992), into the pGEX2T 
vector. The point mutants K107L, K104L and K107L were generated by Dr A.Lim 
(Lim a and Li BF, 1996). They were created by oligonucleotide-directed mutagenesis 
(Amersham) using 5’phosphorylated oligonucleotides  K101L 
(5’pGGTGTTATGGCTGCTGCTGAAGGTTGTGAAA),  
K104L (5’pCTGCTGCTGGGTTGTGAAATTCGGAGAA), K107L 
(5’pCTGCTGAAGGTTGTGCTGTTCGGAGAAGTG), and a single-stranded M13 
template containing the human MGMT cDNA as a BamH1-EcoR1 fragment in 
BlueScript SK. The manufacturer’s protocols were followed. Mutant plasmids were 
transformed into JM109 cells and screened by DNA sequencing. After release from 
the SK plasmid by BamH1 and EcoR1 digestion, the mutant cDNAs were cloned into 
the BamH1 and EcoR1-digested pGEX-2T for expression as GST fusion proteins (Ayi 
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et al., 1992). The GST-MGMT fusion proteins were purified by GSH-Sepharose 
(Pharmacia) following the manufacturer’s protocols. 
 
 
2.5 Assay of MGMT Repair Activity 
The procedures for assaying the repair activities of the wild type and mutant 
GSTMGMT fusion proteins using the 32pCGC6meGCG labeled oligonucleotide were 
described previously (Liem et al., 1994). 
 
 
2.6 Protease V8 Digestion 
Protease V8 digestion was performed by treating 200µg of total cellular protein with 
50ng of V8 (Boehringer Mannheim) in a final volume of 15µl of V8 buffer (50mM 
Tris.HCl, pH 8.0; 0.3M NaCl; 1mM EDTA; 5mMDTT) for 40 min at 37°C. After 
incubation, the reaction was quenched with sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) sample buffer and samples were boiled at 95° for 10 
min. Samples (V8-treated or untreated cellular protein) were then resolved on 15% 
SDS-PAGE and transferred to PVDF membranes (Amersham). 
 
2.7 Cell lysis and Western blot analyses (Immunoblotting) 
Cell pellets were lysed in NP40 buffer (50mM Tris.HCl pH 8.0, 0.5% NP40, 0.3M 
NaCl, 1mM EDTA, 1mM DTT, 10mM NaF, 10mM β-glycerophosphate, 1mM 
sodium orthovanadate, 10% glycerol, 0.2mM PMSF and PI 1:500) on ice for 20min 
followed by centrifugation (14000rpm for 20min at 4oC). The supernatants were 
isolated and protein concentrations were determined using RC-DC kit from Bio-Rad 
(USA). Protein samples were resolved on SDS-PAGE gels, which were prepared with 
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30% acrylamide solution (Bio-Rad catalogue # 161-0516). The samples were then 
transferred to PVDF membranes (Bio-Rad) in transfer buffer (25mM Tris-base; 
192mM glycine; 0.03%SDS) with a Bio-Rad transfer system set at 100V, 350mA for 
2h at 4oC or 30V, 120mA overnight at 4oC. The membranes were blocked with 5%-
skimmed milk in TBST buffer (20mM Tris.HCl pH8.0; 0.15M NaCl, 0.05% Tween-
20) for 30mins at room temperature (rt), followed by three washes with TBST. The 
blot was then incubated with primary antibody either at 37 oC for 1hr or overnight at 
4oC, depending on the antibody used. The filters were then washed with thrice with 
TBST for 5mins at rt before secondary antibodies were added at 1:4000 (anti-mouse 
IgG-HRPO from DAKO) or 1:10,000 (protein-A-HRPO from Transduction 
Laboratories). A final wash, as above, was performed before addition of ECL reagents 
(Amersham) for visualization.  Amersham hyperfilms were used and developed with a 
Kodak X-omatic automatic developer. 
 
2.8 In vitro binding of GST-(wt) and MGMT (K107L) to ERα 
GST-(wt) and MGMT (K107L) were prepared as described previously (Oh et al., 
1996). Recombinant ERα (50ng; Oncogene Science) was added to buffer B (100µl 
50mM HEPES pH 7.3, 0.1% Triton X, 10% glycerol, 100mM KCl and 1mM DTT) 
with glutathione-Sepharose (20µl of a 50% suspension)-bound fusion proteins 
(~100ng) which were first treated with bovine serum albumin (100µl of 20% bovine 
serum albumin in buffer B) at 4°C for 1h. After shaking at 4°C for 30 min, the beads 
were recovered and washed extensively with buffer B before boiling in Laemmli 
buffer for immunoblot analysis. In peptide competition assays, high pressure liquid 
chromatography-purified peptides (Research Genetics) were added to the recombinant 
ERα for 10 min before binding. 
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2.9 In vitro binding of GST-(wt) and GST-p53 to MBP-MDM2 
GST-MGMT (PCR fragment 87-109), GST-p53 (PCR fragment 12-32) and point 
mutants of GST-MGMT / p53 were prepared to perform in vitro binding assay with 
Amylose beads bound MBP-MDM2 (PCR peptide fragment 1-125) as described 
above. Maltose-binding (MBP) protein fusion vector was from New England Biolab. 
 
2.10 Flow Cytometry 
A Becton Dickinson FACScan machine was used to acquire and analyze 21,000 
events (using CellQuest and Modfit). DNA analysis was carried out by propidium 
iodide (PI) staining (50µg/ml at 37°C 30 min in dark) of ethanol (80%; 12h at -20°C)-
fixed and RNase (20µg/ml for 30 min) treated cells. 
 For dual-channel flow cytometry analysis of expressed MGMT and DNA, 
cells transfected with wild-type (wt) and K107L MGMT cDNAs  were fixed in 1% 
paraformaldehyde (30 min on ice) followed by cell membrane permeabilization with 
0.2% Tween 20 and blocking with 10% sheep serum (20°C for 30 min for both steps). 
Mab.3B8 was added to the cells (1h at 37°C) followed by washing two times with 
PBS. After treatment with fluorescein isothiocyanate (FITC) anti-mouse IgG for 30 
min at 37°C followed by washing with PBS, the cells were further processed for PI 
staining as described above. 
 
2.11 Transfection by Superfect® 
 The manufacturer’s protocol (Qiagen) for transfection was followed. 
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2.12 Transfection by Calcium Phosphate precipitation procedure  
Cells were seeded such that it is of about 60% confluence on the day of transfection. 
DNAs to be transfected were mixed together (from 0.5µg to 1µg) in sterile conditions 
and topped up with water to a volume of ~ 440µl (for each 100mm dish) per reaction. 
500µl of 2x HEPES-buffered saline (HBS) (1.6% NaCl, 0.074% KCl, 0.02% 
anhydrous Na2HPO4, 0.2% Dextrose and 1% Hepes Free Acid [pH adjusted to 7.05]) 
was added to DNA mixture slowly and mixed well. 60µl of 2M CaCl2 solution was 
added in a drop-wise manner and mixed well. The mixture was incubated at 37°C for 
30 min, the DNA precipitates were added dropwise to the cells. The cells were left in 
contact with the precipitate for 16-18 h, until the medium was replaced. The exhausted 
media was aspirated and cells were washed with serum-free media (SFM) twice. The 
cells were then re-fed with fresh complete media. After 24h, the cells were harvested 
according. 
 
2.13 ERE / GRE Reporter Assay 
ERE- and GRE- luciferase reporter constructs were generous gifts from Dr. V. Yu and 
Dr. S. W. Chan respectively (IMCB).  ERα and GR were cloned into pXJ-41 
mammalian expression vector (Dr. X.M. Zheng, IMCB). 0.5-1µg of pXJ-41 ER / 
pXJ-41 GR, 0.5-1µg of DNAs of interest (such as MGMT wt and K107L), 0.75µg of 
reporter plasmid and 0.5µg of pCMV-β-gal were used for each reaction. All DNAs 
were transfected into respective cells using Superfect or by calcium phosphate 
precipitation method. After 24h, exhausted media was changed and the cells were 
stimulated with respective ligands (100nM estradiol or 1µM dexamethasone) in 
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respective media containing Phenol-red free culture medium supplemented with 5% 
cdex serum for 16-18h. 
The cells were washed with PBS before lysing with 1x Passive Lysis Buffer 
(Promega) with shaking for 30 min. The cell lysates were then collected and spun for 
2-3 min at 14,000rpm. Supernatants were collected and protein concentrations were 
determined using Bradford Assay with Bio-Rad Protein Assay Reagent. β-gal activity 
assay was performed to correct the variation in transfection efficiency. β-gal assay 
was done by addition of one volume of AB buffer (155mM Na2HPO4, 45mM 
NaH2PO4, 2mM MgCl2, 0.7% of β-mercaptoethanol and 1.33mg/ml o-nitrophenyl β-
D-galactopyranoside (ONPG from Sigma)) to one volume of cell lysate followed by 
30 min incubation at 37°C, till light yellow colour produced. Absorbance was then 
read at wavelength 410nm. Reporter activities were assayed using Luciferase Assay 
System (Promega cat # E1500) as according to manufacturer’s protocol using Turner 
Luminometer TD-20/20. 
 
2.14 Mammalian Two-Hybrid Assay 
Mammalian MATCHMAKER Two-Hybrid Assay Kit (Clontech) were used. V-
MGMT wt or V-K107L mutant were subcloned from pXJ-41 constructs and SRC-1 
fragment (PCR-generated) were ligated in-frame to the VP-16 transactivation domain 
in pVP vector. M-ERα was generated by in-frame ligation of the the ERα to the 
GAL4 DNA binding domain in pM vector. HeLa CCL2 cells were seeded in 6-well 
dishes (Iwaki) to 60% confluent. Cells were then co-transfected with plasmids 
containing 0.5µg of 5xGAL4Luc3 reporter DNA, 0.5 µg pCMV-β-gal, 0.75µg of V-
MGMT wt or K107L or V-SRC-1 and 0.75µg of pM-ER using Superfect reagent 
(Qiagen). Cells were cultured for 24hr, luciferase assay (Promega) and β-gal assay 
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were performed as described previously. Data were obtained from experiments 
performed in triplicate. 
 
2.15 Immunoprecipitation experiments 
Cell pellets were lysed in IP-lysis buffer (50mM Tris pH 8.0, 50mM NaF, 1mM 
EDTA, 1mM DTT, 0.3M NaCl, 20mM β-glycerophosphate, 1mM Na3VO4, 1:500 PI 
and 0.2mM PMSF) and sonicated. Lysates were spun at 30,000 rpm for 30 min at 
4°C. Protein concentrations were determined. Cell lysates (500µg) were incubated 
overnight at 4oC with respective primary antibodies  in IP buffer (50mM Tris.HCl, 
pH8.0, 0.15M NaCl, 5mM DTT, 1mM EDTA, 50mM NaF and PI 1:500). Precipitates 
were captured by 1h incubation at 4oC with anti-mouse / rabbit-FC beads (Sigma). 
After washing extensively with IP buffer, the bound proteins were released from the 
beads with SDS-PAGE sample buffer and analyzed by Western blot using respective 
antibodies. 
 
2.16 Drug/ionizing treatments (section 3.3) 
MCF7 cells (60% confluence) were irradiated at 10Gy using 60Cobalt   source. For 
H2O2 and NMU treatments, cells were changed to serum-free medium (SFM) and 
treated with 0.2mM H2O2 and 0.8mM NMU (freshly prepared in SFM) for 1hr. The 
medium was then replaced with complete medium containing 10% FBS and cells 
were harvested accordingly. Treated cells were fed with 5ml of full medium every 
24hr.  Cell cycle profiles were analyzed by flow cytometric analysis as described 
above. V8 protease analysis of R-MGMT assay was performed using 100µg of cell 
lysates as described above. 
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2.17 Chromatin Immunoprecipitation Assay (ChIP) 
Nuclei were prepared from fresh cell pellets using hypotonic lysis followed by 
Dounce homogenization. After centrifugation (600g) at 4oC for 10min, the nuclei 
were washed with RSB buffer (0.01M NaCl, 1.5mM MgCl2, 0.01M Tris.HCl, pH 7.4 
and PI 1:500) and treated for 10 min at 37oC with 1% formaldehyde (10 volumes). 
The cross-linked nuclei were re-suspended in buffer (200µL containing 1% SDS, 
10mM EDTA, 50mM Tris.HCl, pH8.0 and PI 1:500) and sonicated on ice at 50% 
power output with 9 pulses of 20s. After centrifugation (13,000rpm, 10min, 4oC), the 
supernatants were isolated and protein concentrations were determined. After diluting 
the supernatant (100µg) with 10 volumes IP buffer (0.1% Tween-20; 0.15M NaCl; 
20mM Tris.HCl, pH8.0; 1.2mM EDTA and PI 1:500), respective primary antibodies 
(5µg) were added and the resultant mixtures were incubated at 4oC overnight. The 
immune complexes were recovered using anti-mouse / rabbit-FC IgG-beads. The 
beads collected were washed extensively with IP buffer and the complexes were 
eluted in elution buffer (200µL, containing 1%SDS and 0.1M NaHCO3). Eluates were 
heated at 65oC for 4 hr to reverse the cross-linking. After treatment with Proteinase K 
(Promega, USA) for 1hr at 45 oC, the DNA fragments were then purified by QIAquick 
Spin Kit (Qiagen, Germany). For PCR, 1-3 µl of the DNA extract (50µl) was used. 
Optimized PCR conditions were used for the amplification of promoters / DNAs of 
interest. The PCR conditions for ERα promoter fragments are as follows: PA1 was 
amplified using primer 5’-CTGATGGCAAAATGCAGCTC-3’ (sense) and 5’-
GGGCCTCCAACTTTAAGT-3’ (antisense), 94oC for 5min, followed by 35 cycles of 
94oC for 30s, 58oC for 30s, 72oC for 45s, and elongation at 72oC for 7min; for PA2, 
primers were 5’-GAGTTGTGCCTGGAGTGA-3’ (sense) and 5’-
GGGCCTCCAACTTTAAGT-3’ (antisense), 94oC for 3min, followed by 5 cycles of 
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94oC for 1min, 60oC for 30s, 72oC for 45s, and 25 cycles of 94oC for 1min, 55oC for 
30s, 72oC for 45s, then elongation at 72oC for 3min; for PB1 (NCBI accession number 
AF082876), 5’-TAGAGCATGGGTGGCCATTG-3’ (sense) and 5’-
CGGACACTATGCAGTTACTG-3’ (antisense) were used, 94oC for 3min, followed 












Chapter 3  Results 
 
O6-methylguanine-DNA methyltransferase (MGMT) plays an important role in 
moderating potency of carcinogens because it repairs the mutagenic lesions formed by 
these agents with DNA. This has been demonstrated in vivo by experiments which 
showed that transgenic mice carrying the human MGMT gene (targeted to T-cells) have 
lower incidence of thymic lymphomas when treated with N-methylnitrosourea (Dumenco 
et al., 1993). Furthermore, MGMT-deficient cells, which fail to remove these lesions 
effectively, are susceptible to the cytotoxic and mutagenic effects of these chemicals 
(Daniels and Tainer, 2000a; Pegg, 1990b; Pegg, 1990a; Yarosh, 1985a; Yarosh, 1985c). 
Differential levels of MGMT proteins are observed in cell lines of various origins (for 
example, see Fig 3.1a). For cell lines with MGMT, MGMT level in respective cells 
would be a useful biomarker for monitoring defensive capacity towards damage induced 
by these chemicals. Alternatively, monitoring the level of active-site alkylated MGMT 
(R-MGMT), which is formed specifically from the suicidal repair of O6-alkylguanine and 
O4-alkylthymine in DNA by MGMT, would be a logical indicator for recent exposure to 
chemicals that produce these mutagenic lesions in DNA.  
The de-alkylation reaction by MGMT includes binding of itself to DNA, recognition of 
the O6-alkylguanine lesion, followed by the self-transfer of the alkyl group meG to a 
cysteine residue present at its active site -PCHRV- (amino acids aa144-148 of MGMT). 
The active-site alkylated MGMT, R-MGMT, has been proposed to undergo 
conformational change to favor the degradation of the protein so as to eliminate any 
interference with DNA repair of additional O6-alkylguanine lesions and perhaps, trigger 
the synthesis of additional MGMT proteins that would be needed to maintain the capacity 
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to repair such DNA damage (Pegg et al., 1998; Yarosh, 1985b). Moreover, it has also 
been proposed that the signal for ubiquitination for MGMT is a conformational shift 
resulting from alkylation (Daniels and Tainer, 2000b; Yarosh, 1985d). Fig 3.1b showed 
that upon treatment with O6-benzylguanine (6BG), a pseudo-substrate which inactivates 
MGMT, the level of MGMT is decreased, possibly through ubiquitination and 
degradation (Major et al., 1997b; Srivenugopal et al., 1996b). In addition, it has been 
suggested that the bacterial Ada protein, which serves as an inducible regulator in E.coli 
to confer resistance to the methylating agents (Lindahl et al., 1988; Major et al., 1997a; 
Srivenugopal et al., 1996a), may need to undergo substantial conformational change in its 
structure on binding to DNA in order to expose the active site to the alkyl group on the 
DNA substrate. Upon alkylation of the Ada protein at its NH2-terminal, the protein is 
rendered sensitive to cleavage by trypsin protease, suggesting that conformational change 
may have taken place. Based on the above observations, conformational change in 
















IMR-90 ML-1 MCF7 T47-D
A.
B.
Fig 3.1 Western analyses of MGMT levels. A. Differing levels of 
MGMT in various cell lines. B. MGMT levels in cell lines upon BG 
treatment. 
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3.1 Conformational Change in MGMT Upon Active-Site Alkylation 
3.1.1 Detection of R-MGMT by protease V8 assay using recombinant MGMT 
Probing protein structure with protease sensitivity has been widely used to understand the 
structures of a variety of proteins. Hence, protease assays where two proteases, namely 
protease V8 (which cleaves acidic amino acids aspartic and glutamic) and trypsin (which 
cleaves basic amino acids arginine and lysine) were employed to determine any 
conformational change between MGMT and R-MGMT.  
Due to the disappearance of R-MGMT when cells are exposed to alkylation (Fig 3.1b), 
we also use the recombinant MGMT to study the difference between MGMT and R-
MGMT. R-MGMT was generated using synthetic oligonucleotides containing the 
O6meG.  Our data show a fingerprint cleavage of R-MGMT by V8 protease into 18kDa 
and 14kDa fragments whereas cleavage by trypsin was much less obvious (therefore, 
trypsin assay was not continued, data not shown). Thus, we sequenced the peptides from 
the V8 protease assay to map the cleavage site and it was confirmed that the fingerprint 
18kDa represents single cleavage at the E (glutamic acid) residue whereas the 14kDa 
fragment denotes a double cleavage at E30 and E172. A schematic diagram representing 
detection of R-MGMT to protease V8 assay is shown in Fig 3.2. 
 
3.1.2 Alkylating agents (SN1 and SN2) in the formation of R-MGMT 
The presence of R-MGMT, thus, potentially indicates the exposure to alkylating agents.  
Therefore we use this protease V8 technique to study the effect of SN1 and SN2 agents in 















Fig 3.2. Active-site alkylation induced conformational change detecteable by 
protease V8 assay. A. Illustration showing conformational change upon suicidal 
repair of the 6RG lesion, rendering R-MGMT sensitive to protease V8 cleavage at 
codons E30 and E172. B. CEM cells were treated with different concentrations of 
NMU or the vehicle DMSO as control. Total cell lysates obtained were treated with 
protease V8 and proteins resolved on a 15% SDS-PAGE, MGMT were visualized 
with mAb 2G1. The 18kDa and 14kDa bands indicate the presence of R-MGMT. 
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SN2. SN1 agents are more reactive to the less nucleophilic oxygen atoms while SN2 
agents, predominantly, at the nitrogen atom. 
Treatment of cells with SN1 alkylating agents such as NMU was shown to produce O6-
alkylguanine lesions in DNA. MGMT-mediated repair of such adducts result in formation 
of protease V8 sensitive R-MGMT (Fig 3.3). SN2 alkylating agents such as methyl 
halides are potential human carcinogens (Fostel et al., 1985) and are commonly found in 
our environment (Bolt and Gansewendt, 1993). Although, these agents are ineffective in 
producing O6-alkylguanine, they may directly inactivate MGMT. To determine if these 
agents can produce R-MGMT in cells, we compare the sensitivity of R-MGMT in cells 
treated with a known inhibitor of MGMT, O6-benzylguanine  (6BG, (Dolan et al., 1990)  
and SN2 agents. CEM cells were treated with equal concentrations of SN1 and SN2 
alkylating agents and 6BG at 50µM. As shown in Fig 3.3, SN2 agents such as dimethyl 
sulfate (DMS) produced R-MGMT as efficiently as SN1 agents such as NMU.  
Here, we used MGMT-specific polyclonal (pab.MGMT) and monoclonal (mab) 
antibodies 2G1 for western analysis of the above treated cells. Surprisingly, although the 
polyclonal antibody used here is more sensitive than monoclonal antibody in detecting 
MGMT, it could not detect the 14kDa protease V8 cleavage product. Since the epitope of 
pab.MGMT was mapped at the C-terminal, pab.MGMT could only recognize the single-
cleaved 18kDa fragment. 
As compared to the untreated control or the vehicle DMSO-treated samples, the detection 
of R-MGMT in 6BG-treated samples suggested that 6BG could produce R-MGMT by 
directly alkylating the active site of MGMT. This is consistent with data on loss of 
MGMT repair activity upon 6BG treatment. To verify the efficiency of SN2 drugs in
Fig 3.3 Detection of R-MGMT by protease V8 in CEM cells treated 
alkylating agents and 6BG. Total lysates were obtained from CEM cells 
treated with (1) SN1 agents and (2) SN2 agents at equal concentration of 
1.5mM and 50µM 6BG (a competitive inhibitor of MGMT). Panel a and b:
Immunoblots with polyclonal and monoclonal antibodies to MGMT without 
and with protease V8 treatment respectively. 
Fig 3.4  Comparison of the efficiency between SN1 and SN2 agents in 
generating R-MGMT. Extracts of CEM cells treated with increasing 
doses (0.1, 0.25 and 0.5mM) of SN1 agents NMU and SN2 agent MeI
were subjected to protease V8 assay. MGMT were visualized with 
monoclonal antibodies. 
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generating R-MGMT, a dose-response comparison study between SN1 agent NMU and 
SN2 agent methyl iodide (MeI) was carried out. As seen in Fig 3.4, when CEM cells are 
treated at dosages between 100-500µM NMU or MeI, SN2 agent MeI is more efficient 
than NMU in generating R-MGMT. This is shown by the diminishing amounts of 21kDa 
band remaining after protease V8 treatment (Fig 3.4 b).   
Since MeI does not produce as much O
6
-alkylguanine residues as compared to NMU, 
these data confirmed that R-MGMT can indeed, be generated.  
 
3.1.3 Monoclonal antibody 3C7 preferentially immunoprecipitates R-MGMT 
If R-MGMT adopts an altered conformation resulting in cleavage at E30 and E172 by 
V8, there must be some regions in R-MGMT being “exposed”. Therefore we use 
antibodies generated in our lab to test their abilities to differentiate between MGMT and 
R-MGMT (Ayi et al., 1994). This panel of antibodies was used to detect the presence of 
R-MGMT under native conditions by immunoprecipitation (IP) to preserve the R-MGMT 
structure. Interestingly, one monoclonal antibody, Mab 3C7, can discriminate between 
MGMT and R-MGMT under native conditions (as shown in Fig 3.5).   
Therefore, we applied this technique to study cells treated with MeI and 6BG and 
subjected to IP with Mab 3C7 (see Fig 3.5b2), as compared to the V8 assay to detect R-
MGMT. Formation of protease V8 sensitive R-MGMT is visible at micromolar 
concentrations of MeI and 6BG used. Similarly, R-MGMT is only immunoprecipitated in 
samples with either 6BG or MeI treatment but not in the control DMSO treated extracts 
(see Fig 3.5b1), suggesting that Mab 3C7 specifically recognizes active-site alkylated 
MGMT generated in cells exposed to alkylating agents. Surprisingly, Mab 3C7 IP
Fig 3.5 Comparison between protease V8 assay and immunoprecipitation by 
Mab 3C7  in the detection of R-MGMT. Total cell lysate were obtained from 
CEM cells treated with increasing doses of MeI and 6BG and vehicle DMSO. a. 
Immunoblot analysis for extracts subjected to protease V8 treatment. b. Cell 
extracts (200ug) were immunoprecipitated with Mab 3C7 and immunoprecipitates
visualized by Pab MGMT.
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analysis is much more sensitive than protease V8 assay. While MGMT is barely visible 
by protease V8 when cells were exposed to 12.5µM MeI (see Fig  panel 3.5a2),  Mab 
3C7 IP coupled with western blot showed the presence of R-MGMT even in cells treated 
with 3µM MeI  (Fig  panel 5b2.)  
 
3.1.4 Epitope Mapping of Mab 3C7  
Since the 3C7 epitope may reveal the functions of MGMT as it is potentially exposed in 
R-MGMT, we attempted to map the epitope. Progressive 30-amino-acid deletion mutants 
of MGMT were constructed and bacterially expressed as GST (glutathione-S-
transferase)-fusion proteins (Fig 3.6a and b).  The proteins were analyzed by 
immunoblotting with Mab3C7. It was observed that Mab 3C7 only recognized the full-
length and the deletion mutants containing the residues from codon 90-120 (Fig 3.6c). 
Next, we compared the affinities of the antibodies Mab 3C7 and another monoclonal 
antibody 5H7 towards human and rat MGMT. The western blot showed that Mab 5H7 
could only recognize the human but not the rat MGMT. In contrast, Mab 3C7 could 
recognize both the human and rat MGMT with equal efficiency (Fig 3.6d). Sequence 
alignment showed that the region between amino acids 90-120 in human is highly 
conserved in the rat (Sakumi et al., 1991), the mouse (Shiota et al., 1992) and the hamster 
MGMTs (Rafferty et al., 1992)  (Fig 3.6e).  As the lysine residues at codons 101, 104 and 
107 within this region are highly conserved, we speculated that these basic residues could 
be the recognition epitope for Mab3C7. Point mutations of these lysine residues, whereby 
the lysine is substituted with a leucine (K101L, K104L andK107L), were generated as 
GST-fusion proteins. The proteins were blotted with Mab 5H7 and Mab 3C7. While all
Fig 3.6  Epitope mapping of Mab3C7. 
a) Diagramatic depiction of the deletion fragments constructed, F 
is the full-length MGMT, and fragments labeled 1-9 are the 
deletion mutant proteins. 
b) Coomassie staining of SDS-PAGE gel for the analysis of the 
soluble GST-MGMT deletion mutant proteins. Lanes are 
numbered corresponding to their locations in panel a and the 
arrows indicate appropriate protein bands.
c) Immunoblot of the deletion mutant proteins with Mab 3C7, the 
proteins recognised are fragment 7,8,9 and F.
d) Immunoblot of human (H) and rat (R) MGMT with Mab 3C7 
and Mab 5H7 and the coomassie staining of the gel used to 
resolve the recombinant proteins.
e) Sequence alignment of the mammalian MGMTs at the Mab3C7 
epitope.
f) Point mutants generated at codons 101-107, lysine residues at 
101, 104 and 107 were substituted with leucine (L). The 
bacterial expressed proteins (100ng) each were resolved on 
SDS-PAGE gels and  immunoblotted with Mab5H7 and 3C7. 
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the mutants were recognized by Mab 5H7, Mab 3C7 could only recognize K101L and 
K104L point mutants but not the K107L mutant protein (Fig 3.6f). This indicated that 
residue K107 is the key epitope for Mab 3C7.  As this residue is distal from the active 
site cysteine residue at codon 145, the mapping experiment thus confirms that MGMT 
protein undergoes a drastic conformational change upon active-site alkylation to expose 
the Mab 3C7 recognition epitope. 
 
3.1.5 Characterization of the Mab 3C7 epitope point mutant proteins  
In order to understand the role of Mab 3C7 epitope in the conformational change between 
the active and active-site alkylated MGMT protein, functional characterizations of the 
point mutant proteins within the 3C7 epitopes were performed.  The repair activities of 
these mutants expressed as recombinant proteins in bacteria were assayed using the 
radiolabeled substrate 32p-CGC6MGCG (Liem et al., 1994) and the  protein 
conformation was studied by protease V8 assay.  As shown in protease V8 digest (Fig 
3.7a), mutant K107L alone is cleaved by protease V8. The cleaved products were of the 
identical size to those generated by the active-site alkylated wild-type (wt) fusion protein 
(Fig 3.7a). Repair activity assay indicated that K107L mutant had no detectable repair 
activity although some residual activities were observed for K101L and K104L mutant 
proteins, which explained their insensitivity to protease V8 (Fig 3.7b).  These results 




































A. Protease V8 digestion
B. Repair Activity
Fig 3.7  Properties of K101L, K104L and K107L of GST-MGMT
point mutation fusion proteins. 
A. 50µg of bacterial protein lysates for GST-MGMT wild-type (wt), 
K101L, K104L and K107L were digested with 100ng protease V8 at 
37oC for 20mins, the reaction quenched by Laemmli loading buffer and 
proteins resolved on 13.5% SDS-PAGE gel. Proteins were 
immunobotted with MGMT antibody.
B. Repair activity assay of the GST-MGMT (wt) and point mutants. 
Duplicate samples of the purified GST-fusion proteins (50 µg) were 
incubated with substrate 5’32pCGC6MGCG (approximately 85000 
cpm/10pM) at 37oC for 10mins. The reaction were quenched and 
analyzed for the prooduct 32pCGCGCG and the substrate  
32pCGC6MGCG. Four HPLC runs (duplicate of two injections per 
sample) were carried out for each protein. The average cpm of te product 
32pCGCGCG and the unrepaired substrate 32pCGC6MGCG are 
summarized in columns 2 and 3. N.D., not detectable. Column 4 
represent the percentage of repair calculated from the ratio of the 
product cpm to the sum of product and residual substrate cpm detected. 
Column 5 shows the percentage efficiency of repair with respect to the 
wt protein.
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3.1.6 Discussions  
MGMT repairs DNA by transferring the alkyl adducts from O6-alkylguanine in DNA to 
the acceptor cysteine residue at its active site (formation of R-MGMT). This transfer 
process does not require any cofactor and the DNA is restored completely. However, this 
repair process is ‘suicidal’ as MGMT is irreversibly inactivated and hence, the capacity 
of repair is dependent on the amount of MGMT and its constitutive rate of synthesis. 
R-MGMTs formed in cells exposed to alkylation are the result of repairing O6-
alkylguanine adducts produced in the DNA by alkylating agents, i.e., by an indirect 
pathway. Here, we demonstrated that R-MGMT can also be generated by direct 
alkylation of the active site of the protein by SN2 agents and competitive inhibitor O6 –
benzylguanine. Having shown that SN2 agents are as effective as SN1 agents to 
inactivate MGMT (as compared to SN1 agents), it cautions us against the potential 
hazards of SN2 agents, such as methyl halides, which are commonly found in the 
environment. 
Here, R-MGMT has been shown to adopt a conformational change. This altered 
conformation results in the exposure of novel epitopes that can be detected by its 
increased sensitivity to protease V8 (codons E30 and E172) and by binding to Mab 3C7 
(around K107). 
The hypothesis on the conformation change of MGMT was made based on the available 
X-ray structure of the 19 kDa C-terminal domain of the Escherichia coli ada gene 
product (Moore et al., 1994). Though there is no significant primary homology in the N-
terminal domain between Ada and MGMT, they exhibit a conserved α/β roll. Both Ada 
and MGMT have a three stranded anti-parallel β-sheets followed by
Fig 3.8a Comparison of sequence and secondary structure of Ada-C and 
hMGMT. (A) Sequence alignment of hAT (G177stop) with the C-terminal 
domain of Ada constructed according to topological equivalence. Fully 
conserved residues in the AT family are shown boxed (purple). Secondary 
structural elements and their labels as referred to in the text are shown above and 
below the sequences for hAT and Ada, respectively. These elements are colour
coded as follows:   -helices are shown in blue except for H3 and H4 forming the 
helix–turn–helix element (green), ß-sheets in red and a single turn of helix is 
shown in cyan. The Ada-C sequence is numbered by renaming T176 in the full-
length Ada as residue 1. The numbers running above the hAT sequence refer to 
residue numbering for hAT only. (B) Stereo drawing of the human O6-
alkylguanine-DNA alkyltransferase showing the principal secondary structural 
elements colour coded as in (A). In addition, the four residue turn of the active 
site residues C145–R148 are shown in yellow and labelled -CHR-. The N- and C-
terminal residues are marked, as are the sequence numbers 36 and 42, indicating 
the undefined loop residues.  (Adapted from Moore et al., 1994).
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two α-helices. Sequence alignment of 3C7 epitope and the Ada protein positioned 3C7 
epitope on the coil region C3 of Ada between the helices 3 and 4 (a helix-turn-helix, 
HTH motif). It faces the active-site-PCHRV- motif which is located on a long coil 
between helices 5 and 6. From the structure, the 3C7- containing coil C3 was masked by 
coil C5 and this rendered the 3C7 epitope inaccessible. It appears that the front and back 
of C5, the analogous Mab3C7 epitope of Ada-C, and helix 6 encompass the active site.  
In this structure, H147 in the active-site motif of Ada and the E173 residue were linked 
via hydrogen bonding. These residues correspond to H146 and E172 of the human 
MGMT. This interaction between the H146 and E172 residues appeared to serve a crucial 
role in maintaining the protein conformation as mutations of either H146 or E172 of 
MGMT severely impaired the repair activity (Chueh et al., 1992; Rafferty et al., 1994). 
This provides an explanation to our observation that the H146 and E172 physical 
interaction in repair-active conformation (i.e. active MGMT) protects E172 from protease 
V8.  Subsequently, the crystal structures of MGMT were solved (Daniels et al., 2000; 
Wibley et al., 2000). While direct structural studies of MGMT-DNA are not yet 
available, several models of how MGMT may bind DNAs have been proposed where 
there is a helix-turn-helix (HTH) motif which potentially binds to DNA. Since the O6-
alkyl-deoxyguanosine residue mostly in small DNA duplex flips out from the DNA 
double helix, this residue may fit into the binding pocket of MGMT. The HTH DNA-
binding domain spans from residues Q115 to G136 of MGMT. Within this HTH motif, 
residue R128 is important in stabilization of the O6-alkylguanine residue in the 
crystallized R-MGMT. This explained that mutation of arginine 128 to leucine (R128L) 
decreased the repair activity of MGMT (Lim and Li, 1996). The binding pocket contains 
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the acceptor cysteine residue, C145, at the active site. The C145 residue forms an 
extensive hydrogen-bonding network with the surrounding Y158, H146 and E172 
residues via a water molecule. Proton abstraction occurs through this hydrogen bond 
network to assist nucleophilic attack by C145 to release the target with other surrounding 
O6-alkyl group of O6meG captured by activated cysteine to form S-alkyl-cysteine and the 
DNA structure is restored. 
With the knowledge of the structure of MGMT (see Fig 3.8b) and the available x-ray 
structure of Ada, we hypothesized the following. Although E30 in MGMT is similar to 
E172 in susceptibility towards protease V8 only when the active-site is alkylated, we 
could not conclude that it shares the same hydrogen bonding to the active-site domain as 
E172. Therefore, we proposed that E30 may be interacting with the basic (positively 
charged) residues within the 3C7 epitope, residues 101-107, KLLKVVK since protease 
V8 assay showed that the K107 mutant cleavage is similar to R-MGMT. 
During the repair process, the binding of the recognition helix preceding the Asn-hinge 
(asparagine-hinge) to the DNA, where the alkyl groups of 6meG collide with Asn137 is 
likely to disrupt the three hydrogen bonds of the Asn137 side chain. This will open up the 
Asn-hinge which is important for the protein stability (Crone et al., 1996) for maintaining 
the tertiary structure of MGMT. When this occurs, it will allow the helix containing the 
3C7 epitope, which is located in close proximity to the Asn-hinge, to be unmasked and 
the interaction between E30 and the 3C7 epitope disrupted. Since the alkylation of the 
active-site C145 is irreversible, therefore, R-MGMT adopts an altered conformation 
change. A schematic diagram depicting the exposure of E30, E172 and 3C7 epitope of 
MGMT conformational change is shown in Fig 3.9. 
Fig 3.8b Human AGT secondary structure, two-domain fold, zinc site, and location 
of structurally and catalytically critical residues. (A) Overall fold, displaying the 
active site cysteine (yellow) and its surrounding hydrogen-bond network, zinc 
(purple) ligands and Arg128 `arginine finger'. A central interdomain cleft separates 
the N-terminal  α / β roll (α -helices in royal blue, β -strands in orange) from the C-
terminal domain, which contains the active site and HTH DNA-binding motif (sky 
blue). For continuity, the location of the internal disordered loop (purple) has been 
interpolated. (B) Primary sequence, secondary structure and residue function of 
human AGT aligned with the E.coli Ada-C protein. Identity between the two 
sequences is shown with an asterisk, while corresponding residues that lie within 
4.5 Å in the overlaid structures are given in upper case letters. The conserved active 
site motif (yellow boxes) is flanked by residues defining the O6-alkylguanine-binding 
channel (green boxes), anticipated DNA-binding residues (orange boxes), and HTH 
motif, with its associated Arg128 (sky blue). Colors distinguish residues participating 
in the active site hydrogen-bond network (red), zinc ligands (purple),   -helices (royal 
blue) and 310-helices (navy blue). [Adapted from Daniels DS, et. al., 2000.]
Fig 3.9 Schematic Diagram depicting the exposure of three 


















3.2 Role of R-MGMT in the regulation of Estrogen receptor 
3.2.1 Proteins homologous to the Mab3C7 epitope 
What is the function of this conformation change from MGMT to R-MGMT? The 
Mab3C7 epitope encompasses the region around codon 91-110 and contains the 
VLWKLLKVV domain. Homology search of the 3C7 epitope in R-MGMT reveals 
similarity to transcription co-activators and MDM2/p53 interaction domain. This leads us 
to study the function of R-MGMT in more detail. 
 
3.2.2 Effect of R-MGMT on the growth of ER-expressing cells 
In our study on the function of R-MGMT, we have treated a number of cells with the 
MGMT inhibitor 6BG. Interestingly, the flow cytometry analysis of these BG-treated 
cells showed the retarded cell growth (see Fig 3.10a) of the breast cells MCF7 and T47D 
as they have high G1 but low S phase cell populations as compared to BT549 and MDA-
MB231 (breast cells), HeLa CCL2 (cervical) and the SV40-transformed lung cancer cells 
MRC5.SV40. The characteristics of these cells are summarized in the western blot in Fig 
3.10B. Interestingly, MCF7 and T47D cells which express MGMT and ERα proteins are 
affected by 6BG treatment. The western blot also showed that all MGMT in the 6BG-
treated cells are all converted to the V8 sensitive R-MGMT, irrespective of their origins 
(Fig 3.10b). Furthermore, the levels of ERα and nuclear receptor co-activator protein 
SRC-1 did not alter with 6BG treatment (Fig 3.10c and 3.10d), suggesting that R-MGMT 








Fig  3.10 Growth retardation of ER+ MGMT+ breast cells induced by 6BG    
treatment.
A. Flow cytometric analysis profile of cells treated with 60µM of 6BG for 15h
B. Western analysis of MGMT and R-MGMT in cell lysates. Cell lines are 
numbered as in panel A. Control indicates untreated samples, whereas 6BG 
indicates treated samples. Control + V8 and 6BG + V8 panels showed the 
protease V8 assay profile to identify presence of R-MGMT.
C. Immunoblot of ER for panel B
D. Immunoblot of SRC-1 for panel B
E. Table showing the phenotypes of the cell lines used in panel A
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To understand the mechanism behind the ERα+/MGMT+ upon 6BG treatment as a result 
of R-MGMT, we studied the characteristic of the MCF7 and T47D, by culturing them in 
the absence of estrogen-like stimulant (culture medium without phenol red and 
supplemented with dextran-coated charcoal stripped serum, cdex medium) as compared 
to 6BG treatment. Fig 3.11A and B showed that these cells failed to grow in cdex 
medium with no estrogen stimuli and they showed similar lower S-phase populations  
(Fig 3.11C and D) as cells grown in full medium (i.e. with estrogen stimuli) with 6BG. 
Thus, the growth of these ERα+ cells is entirely dependent on estrogen-stimuli or driven 
by ligand-activated ERα, suggesting that treatment of 6BG affects the ERα–mediated 
cell proliferation. 
To ascertain these affects are due to R-MGMT but not some unknown effect of 6BG (in 
acting as an anti-estrogen); we generated R-MGMT independently by treating these cells 
with MeI (see Chapter 3.1.2). Flow cytometric analysis of these cells showed that while 
E2 stimulated the growth of these cells, treatment with MeI in the presence of E2 
behaved similarly in blocking E2-stimulated growth on cells grown in cdex medium (Fig 
3.11C and D). Since MeI has an entirely different chemical structure as compared to 6BG 
and they both produce R-MGMT (Fig 3.11E and F), we can conclude that R-MGMT 
inhibits proliferation of ERα+ cells. The above results lead us to speculate whether there 
is a close relationship between R-MGMT and ERα. 
 
3.2.3 Cell cycle arrest by 6BG and MeI is independent of p53 
Since MeI but not 6BG induces DNA-damage, any cell-cycle arrest resulting from the 





































































Fig 3.11 R-MGMT inhibits E2-stimulated growth of ER-positive 
cells. A and B, Profiles of MCF7 and T47D cells obtained from culturing 
in full medium (ctr), cdex medium or treatment with BG for 15h. C and
D, Bar chart plotted to summarize the percentage of cells at each phase 
of cell cycle in cdex treated (Cdex), stimulated with E2 for 15h (E2) or 
treated wit 6BG and MeI prior to E2 stimulations, E2+6BG and E2+MeI 
respectively. E and F, protease V8 assay to detect the R-MGMT present 



































Fig 3.12 Cell cycle arrest induced by 6BG and MeI is independent of p53. 
MCF7 cells were exposed to 2Gy of γ-irradiation (60Co source), 60µM of BG and 
1mM of MeI. Cells were harvested at 1,3 and 6h post treatment. A and B, 
immunoblot analysis; C, protease V8 assay and D, flow cytometric analysis of 
cells 24h post treatments. G1,S and G2 denotes the cell cycle phase.  
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from treatment with MeI and γ-irradiation which is known to induce p53-mediated cell 
cycle arrest. Fig 3.12A showed that the level of p53 in γ-irradiated MCF7 cells is 
significantly higher than those cells treated with MeI or the non-DNA damaging agent 
6BG. Since γ-irradiation does not induce protease V8 sensitive R-MGMT (Fig 3.12C), it 
appears that the cell cycle arrest (Fig 3.12D) induced by 6BG and MeI is mediated by R-
MGMT independent of p53. Furthermore, T47D cells which express high level of mutant 
p53 also undergo cell-cycle arrest upon MeI and 6BG treatments as well (data not 
shown). 
 
3.2.4 R-MGMT Interacts with Estrogen Receptor (ERα) in vitro 
Since R-MGMT adopts an altered conformation to expose the LWKLL domain 
containing the LXXLL motif (Dumenco et al., 1993; Heery et al., 1997) found in steroid 
hormone co-activators which is critical for binding of co-activator to nuclear receptors, as 
well as the specific inhibition of the growth of ERα+ cells by 6BG, we study the role of 
R-MGMT in ERα-mediated cell growth. This is important because cell proliferation may 
be blocked by R-MGMT. Furthermore, active MGMT is localized at the active 
transcription sites (Ali et al., 1998b) where active transcribing estrogen receptor (ER)-
regulated genes may occur.  We first determine if R-MGMT interacts with ER. GST-
MGMT wt and K107L fusion proteins were used in pull-down experiments.  
Immobilized GST wt and K107L mutant proteins were incubated with purified 
recombinant ERα protein (Fig 3.13A).  The bound complexes were resolved on SDS-
PAGE gel and visualized with antibodies to ERα and MGMT. The ERα was detected in 























































Fig 3.13 R-MGMT Interacts with Estrogen Receptor (ERα) in 
vitro.
A. The scheme for GST-MGMT K107L mutant pull down assay
B. Recombinant ER pulled down only by GST-K107L protein. 
C. Peptide competition assay. Synthetic peptides contining the 
wild-type LXXLL motif or mutant LXXAL motif were 
added to ER prior to binding to immobilized GST-K107L 
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SRC-1: S-------LHRLL-------D


















































































































D. Mammalian two-hybrid assay. Top panel shows the region of 
SRC-1 used and similar size fragment to full length MGMT 
K107L was designed. Constructs were fused to VP-16 activation 
domain containing vector and used to interact with ER protein 
fused to GAL4-DNA-binding domain containing vector. Lower 
panel shows the average reporter activities obtained from 
triplicate experiments assayed in HeLa CCL2 cells, the activities 
were normalized to β-Gal activities.
E. Mammalian two-hybrid assay in the presence of BG assayed as in 
Fig D except MRC5. SV40 cells were used.
 81
determine if the exposed LWKLL motif of R-MGMT is indeed involved in this 
interaction, synthetic peptides containing the LXXLL motifs of MGMT and NR co-
activator CBP were added in GST pull-down experiments (Fig 3.13C). These peptides 
were mixed with purified ERα protein prior to pull-down by immobilized GST-K107L 
mutant protein. The interaction of K107L and ERα is disrupted or competed out by the 
WT LXXLL containing peptides (Fig  3.13C, lanes 1 and 3) but not peptides containing 
leucine (L) to alanine (A) mutation (Fig  3.13C, lanes 2 and 4). These data demonstrate 
that R-MGMT interacts with ERα via LXXLL motif similar to that of nuclear co-
activator (NCoA).  
To further confirm these observations in vivo, we use the mammalian two-hybrid assay to 
study whether the K107L-MGMT can stimulate the activity of the reporter Gal4-DNA 
binding domain fused to ER in HeLa cells. We use comparable same size fragment 
(amino acids 147-354) of SRC-1 containing the NR box as control. Fig 3.13D showed 
that, indeed, the reporter is activated, indicating the direct interaction between R-MGMT 
and ERα in vivo. Similar results were obtained in MRC5.SV40 cells, which do not 
express both MGMT and ERα (Fig 3.13E).  Furthermore, treatment of the Wt-MGMT 
sample with 6BG (which converts Wt-MGMT to R-MGMT) facilitates the interaction 
between the two constructs as shown by the increase in luciferase reporter activity as 
compared to untreated sample (Fig 3.13E). Taken together, these data indicate that R-
MGMT interacts with ERα via its LWKLL motif as illustrated in Fig 3.19 (see p36).  
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3.2.5 Interactions of endogenous R-MGMT and ERα 
To address whether endogenous R-MGMT and ERα interact in vivo, breast cancer cell 
line MCF7 expressing both MGMT and ERα (see Fig 3.14 input lane) was used.  These 
cells were treated with alkylating agent MeI (1mM) and 6BG (50µM). The cell lysates 
obtained were incubated with an ERα-specific antibody to determine whether 
immunoprecipitates of ERα contain MGMT. Western blot analysis of the 
immunoprecipitates showed that MGMT was present in the ERα immunoprecipitates 
only in cells treated with MeI and 6BG (see Fig 3.14) when similar amount of ERα was 
immunoprecipitated in both the control (Ctr) and treated cells. These results further 






























Fig 3.14  Endogenous ER  interacts with R-MGMT. Extracts from MCF7 
cells untreated (Ctr) or treated with 6BG or MeI were incubated with ER 
specific antibody, PabH184. The co-immunoprecipitated proteins were 
identified by western blotting with ER (MabF10) and MGMT (Mab 3b8) 
antibodies.            
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3.2.6 MGMT K107L mutant resembles R-MGMT-mediated G1 arrest in MCF7    
          cells 
To investigate if the LXXLL motif of MGMT is responsible for the cell-cycle arrest 
observed upon MeI and 6BG treatment, we studied the effect of MGMT wt and K107L 
mutant expressions [which mimics R-MGMT (see section 3.1)] on the cell cycle.  MCF7 
cells were transfected with MGMT wt and K107L mutant expression constructs or the 
empty vector. The transfected cells were harvested at 24hr, fixed and stained with 
propidium iodide (PI) and MGMT-specific monoclonal antibody Mab3B8. The samples 
were analyzed by flow cytometry using dual channels to quantify the fluorescence signal 
from MGMT antibody staining and the DNA content from PI staining.  As shown in Fig 
3.15, expression of K107L mutant resulted in an increase in the G1-phase cell population 
when compared to the wt-transfected cells or control experiment.  
This data suggests that expression of R-MGMT induces predominant G1 phase arrest in 
ERα-positive MCF7 cells as shown by the arrow in Fig 3.15f via its exposed LXXLL 
motif, in contrast to LXXLL motif in co-activators which activate ERα in transcription of 
NRE-mediated genes.  
 
3.2.7 R-MGMT affects ER-mediated transcription complex 
Since ERα-mediated transcription requires its interaction with the LXXLL NR box of co-
activator proteins (such as SRC-1; Onate et al., 1995; Parker, 1998) and co-regulator 
proteins (such as CBP/p300), we tested whether R-MGMT utilizes its exposed LXXLL 
motif to disrupt the ER-SRC-1 interaction.  MCF7 cells were treated with MeI and 6BG 
and the lysates subjected to IP with an SRC-1 specific antibody. Fig 3.16a showed
Fig 3.15 Overexpression of K107L induces cell cycle arrest in MCF7 cells. MCF7 
cells were transfected with WT or K107L expression plasmids and empty vector (Ctr) 
for 24h. Cells were harvested and analyzed by flow cytometry. a-c, shows the 
distributions of the transfected cells stained by Mab 3B8 (FL1-A, y-axis) and the DNA 
content (FL2-A, x-axis). Cells with greater MGMT staining than ctr, indicating 
expression of the cDNAs are gated (region R).  d-f, histograms of the gated cells 
showing cell population (y-axis) versus the cell cycle represented by x-axis.
G1
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significantly more ERα was precipitated by SRC-1 antibodies from the untreated control 
sample as compared to samples treated with MeI and 6BG, which contain R-MGMT. 
Conversely, when an ERα specific antibody was used for IP, R-MGMT co-precipitated 
with ERα in 6BG and MeI-treated samples (Fig 3.16b). From these data, it showed that 
R-MGMT promote the dissociation of ERα from SRC-1. However, this dissociation may 
also be due to the direct effects of 6BG and MeI on the ERα-SRC-1 complex, but 
independent of R-MGMT.  To discount this possibility, we generated MRC5.SV-ER cells 
which stably express ERα but are MGMT-, since there are no estrogen responsive breast 
cells exhibiting ERα+ MGMT- phenotype (Fig 3.16c). These cells were treated similarly 
with 6BG and MeI. But unlike the ERα+/MGMT+ MCF7, the ERα-SRC-1 
immunoprecipitable complex remained intact in these ERα+/MGMT+ cells (Fig 3.16d). 
Taken together, these results demonstrate that R-MGMT disrupts the ERα-SRC-1 
complexes and sequesters ERα from SRC-1 in activating cell proliferation, or the R-
MGMT growth inhibition observed. 
To identify what targets MGMT to the proximity of ERα-SRC-1 complexes, we test if 
MGMT can associate with CBP/p300, which is a known transcription co-regulator for 
numerous nuclear receptor-co-activator complexes  (Torchia et al., 1998). As shown in 
Fig 3.16e, the MGMT co-precipitated with CBP/p300 only in untreated and not in the 
treated cells. This data suggests that conversion of MGMT to R-MGMT may shift 
MGMT’s association with CBP/p300 at the active transcription sites for any DNA-

































































































Fig 3.16 R-MGMT disrupts the ERα-SRC1 interaction and fails to associate with
CBP/p300.
A. Immunoblot of SRC-1 and ERα in SRC-1 immunoprecipitates from MCF7 
nuclear extracts. Cells are untreated (ctr), or treated with 1mM MeI (MeI), and 
50µM BG (6BG) for 2h.Top panel, SRC1 precipitated by antibody to SRC1 
(Mab.677-F11). Lower panel, ERα co-precipitated by SRC1.
B. Western analysis of ERα (Mab F10) and MGMT or R-MGMT (Mab 3B8) in ERα
immunoprecipitates (using Pab H184).
C. Absence of ERα + MGMT- phenotype breast cancer cell line.
D. Immunoblot analysis of SRC-1 and ERα in SRC1 immunoprecipitates from 
MRC5.SV-ER cells (ERα+ MGMT-) similar to A. The ERα-SRC1 complex was 
not affected by MeI or 6BG treatment.
E. Immunoblot of MGMT and CBP in CBP/p300 immunoprecipitates, similar to A.
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3.2.8 R-MGMT inhibits ERα transcriptional activity 
Considering the disruptive effects of R-MGMT on the SRC-1-ERα complexes which 
lead to inhibition of ER+-mediated cell proliferation, we investigated whether the 
LWKLL motif in R-MGMT affects the transcriptional activity of ERα. Full-length 
MGMT wt and mutant MGMT constructs (Fig 3.17A) were co-transfected into 
MRC5SV-ER cells with an (ERE)2-vit-luciferase reporter construct.  As shown in Fig 
3.17B, the reporter activity for Mu (K107L or R-MGMT) construct was significantly 
reduced as compared to control (ctr) or the sample containing the wt construct, whereas 
wt-2A and the mu-2A (mutant K107L with its LXXLL motif mutated to LXXAA) 
constructs containing mutations in the LXXLL motif do not affect the reporter activity. In 
summary, these data demonstrate that R-MGMT inhibits the growth of ERα+ cells by 
inhibiting ERα+-mediated transcription of ERE-responsive genes. 
   
3.2.9 Interaction and regulation of other nuclear receptor(s) by R-MGMT    
Since R-MGMT interacts with ERα, a member of a large family of highly conserved 
nuclear receptors, we sought to determine specificity of the LWKLL motif in R-MGMT 
in binding to other nuclear hormone receptors belonging to the same nuclear receptor 
family as ERα, such as the Glucocorticoid receptor (GR). GR activates the transcription 
of GRE similar to ERα on ERE as it requires co-activators that regulate transcription by 
remodeling chromatin or by facilitating the recruitment of the basal transcriptional 
machinery. Co-activators of GR are often found in multi-protein complexes for other NR 
as well as GR. These complexes therefore mediate the activity of other nuclear receptors 
and transcription factors   (Jenkins et al., 2001).  
ERE-Luc   : ERE-TK-Luciferase 
Wt        : M---QVLWKLLKVVKF--(FL)
Mu (K107L): M---QVLWKLLKVVLF--(FL)
Wt-2A     : M---QVLWKAAKVVKF--(FL)













































































Fig 3.17  Effect of R-MGMT on ERα-mediated transcriptional activity. A. 
Abbreviations of the wt and Mu (K107L mutant) MGMT full length constructs 
used in the reporter activity assay. B top panel, immunoblot of the ERα (Pab
HC20) and the various MGMT proteins (Pab MGMT) in SV-ER cells. Cells 
were cultured in cdex medium for 24hr after cotransfection of MGMT 
constrcucts and the reporter plasmid followed by 6h treatment of 1µM of E2. 
Luciferase activity obtained from duplicate experiments.
B.
Fig 3.18 R-MGMT’s effect on glucocorticoid receptor. A, Flow 
cytometric analysis of MDA-231 (1) and HeLa CCL2 (2) treated with 6BG 
and dexamethasone (dex) for 36hrs under cdex medium. B, immunoblot of 
MGMT and GR in total cell lysates. Cell lines labeled as in panel A. ctr, 
untreated; 6BG, cells treated with 6BG. 6BG +V8, cell lysates digested 
with protease V8 to detect R-MGMT. C, immunoprecipitation of GR in 
HeLa and MDA-231lysates, co-precipitated MGMT or R-MGMT analyzed 
using Mab3B8, blot reprobed to show GR protein immunoprecipitated. D,
GR-mediated transcription activity assay. HeLa CCL2 cells were 
transfected with GR and MGMT wild-type (WT) or mutant (Mut, K107L) 
or Mut with LXXLL motif mutated to LXXAA and a luciferase reporter 
plasmid containing 2XGRE element. Luciferase activity was normalized to  
β-galactosidase (β-gal) activity to correct for differences in transfection























HeLaCCL2 cells which express both GR and MGMT (GR+/ MGMT+) and MDA-231, 
which expresses GR but not MGMT (ie. GR+/MGMT-) were treated with GR ligand 
dexamethasone (Dex) with or without 6BG to determine the effect of MGMT/R-MGMT 
on Dex-mediated growth repression.  Flow cytometric analysis showed that in HeLa 
CCL2 cells, Dex treatment resulted in G1 arrest. However, this Dex-mediated arrest was 
override when cells were co-treated with BG (Fig 3.18A2). This effect was not observed 
in MDA-231 cells that do not express MGMT (Fig 3.18A1). These data showed that R-
MGMT potentially regulates the function of GR in HeLa CCL2 as BG treatment 
generates the presence of the protease V8 sensitive R-MGMT (Fig 3.18B). IP experiment 
with GR antibody showed that R-MGMT co-immunoprecipitated with GR (Fig 3.18C) in 
BG-treated cells, indicating that the interaction between R-MGMT and GR may abrogate 
the Dex-mediated arrest.  
To investigate this, HeLa cells were transiently transfected with luciferase reporter vector 
containing two GRE elements and GR expression plasmid in the presence or absence of 
MGMT wt and mutant (K107L) expression vectors. This assay revealed that K107L-
MGMT suppressed Dex-induced GRE reporter activity (Fig 3.18D bar 4) but not the wt 
and mut-2A. Together, these data confirm that R-MGMT modulates GR activity by its 
direct association of GR via its exposed LXXLL motif similar to ERα in Fig 3.19. 
 
3.2.10 Discussions 
In this study, physical and functional interactions between nuclear receptors (estrogen 
and glucocorticoid receptors (ERα and GR respectively) and the active-site alkylated 
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Fig 3.19  Schematic model showing how R-MGMT (as a 
result of treatment with BG) regulates nuclear receptors 
ERα and GR. 
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With the observations of MGMT converting to R-MGMT by the V8 protease assay and 
the prominent G1 arrest upon 6BG treatment in MCF7 cells, we raised the question if 
6BG or the resultant R-MGMT is responsible for such growth arrest. As these breast cells 
are estrogen-responsive cells whereby estrogen stimulates cell growth, the experiments 
planned to eliminate anti-estrogenic effects. Estrogen depletion and even possible 
involvement of tumour suppressor p53 showed that R-MGMT, generated by either 6BG 
or MeI, was responsible for the observed growth arrest. This data prompted us to 
investigate what exactly is the characteristic of R-MGMT that caused the growth arrest 
and the mechanism behind it. Since ERα is crucial in driving the transcription of its 
responsive genes and mediation in growth in MCF7 cells, we proceeded to determine the 
role of R-MGMT in regulation of ERα function.  
It is known that that transcription regulation by nuclear receptors (NRs) occurs through 
direct interaction with the transcription machinery or via recruitment of co-regulator 
proteins that facilitate interaction with the transcription machinery (Glass and Rosenfeld, 
2000; McKenna and O'Malley, 2002; Robyr et al., 2000). Co-activators, such as SRC-1, 
associate with the LBD of NRs via a small α-helical motifs with a consensus motif 
LXXLL (Heery et al., 1997) and sequences flanking this motif are required for specific 
interaction with different NRs (Darimont et al., 1998; Heery et al., 2001; McInerney et 
al., 1998).  
Since the LXXLL motif exposed in R-MGMT is similar to that of the NR box present in 
nuclear co-activators and is required for interaction with NRs, R-MGMT would 
potentially function as a co-activator. However, in vitro and in vivo experiments have not 
only confirmed the interactions between ERα and R-MGMT via the LXXLL motif but 
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also showed that R-MGMT competes with co-activator SRC-1 to associate with 
ERα, resulting in cell-cycle arrest. This observation contradicts the role of LXXLL motif 
-containing proteins that generally act as co-activators for transcription and concludes 
that R-MGMT acts as a co-repressor.  
While nuclear receptor co-repressors generally contain a CoRNR box (with consensus 
sequence of LXXXIXXXI/L) for binding to NRs, R-MGMT, shown to be a co-repressor 
in ERα-mediated transcription, does not contain this CoRNR box. This box, however, 
utilizes the same NR surfaces as the LXXLL motif in co-activators. Hence, as a co-
repressor, R-MGMT competes with co-activators containing this same LXXLL motif; 
and competition assay showed that R-MGMT could disrupt ERα/SRC-1 complexes. 
So, what is the implication in R-MGMT acting as a co-repressor? Such disruption of the 
co-activator from the receptor by R-MGMT provides timely suppression of 
ERα−mediated cell proliferation when cells are exposed spontaneously to alkylating 
agents. This serves two immediate functions. Firstly, cells proliferating under the control 
of ERα will not enter S-phase upon exposure to alkylating agents, thus avoiding O6-
alkylguanine-directed mutations during DNA replication. Secondly, even though 
alkylating agents can inflict damage on the transcribing DNA of ERα−regulated genes, 
this DNA will be blocked from transcription to prevent the instant formation of mutated 
RNA. Thus, the “suicide” of MGMT upon repair of the O6-alkylguanine lesions 
immediately converts the DNA repair enzyme to a transcription repressor (R-MGMT) 
and allows it to directly couple detection and  the subsequent response specifically to the 
insult of the alkylating carcinogens. This mechanism should ensure that ERα would not 
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activate proliferation of cells with damaged DNA, so that genomic integrity could be 
maintained.   
On the other hand, GR, a member belonging to the same nuclear superfamily as ERα, 
was chosen to determine the binding specificity of R-MGMT. Glucocorticoids, as 
opposed to estrogens, are known to exert antiproliferative effects in a number of different 
tissues and cell types (Greenberg et al., 2002), including HeLa CCL2. 
Here, R-MGMT was not only shown to be involved in regulation of ERα-mediated cell 
growth, it was also involved in GR-mediated growth repression. Similarly, as shown in 
the Dex with or without 6BG-treated HeLa CCL2, it has been demonstrated that R-
MGMT interacts with GR via the exposed LXXLL motif and represses GR-mediated 














3.3 Role of MGMT and BRCA1 in the regulation of Estrogen receptor 
3.3.1 The relationship between MGMT and ERα proteins 
In summary, the previous experiments showed that R-MGMT exposed a domain which 
binds to ERα (or GR) similar to nuclear receptor co-activator. This interaction leads to 
inhibition of ERα-mediated transcription and cell proliferation. ERα is thought to play a 
major role in mammary epithelial cell proliferation during carcinogenesis. Interestingly, it 
has been reported that the elevated expression of MGMT in human breast ductal 
carcinoma cells (as compared to normal breast cells) appeared to be a general 
characteristic of breast tumors (Wani and D'Ambrosio, 1997). Since we noticed the ERα 
+ and MGMT− phenotype absent in some of the breast cells we analyzed (Fig 3.20), we 
raise the question of whether MGMT has a potential role to cause aberrant ERα activity 
as observed in breast cancer. These observations prompted us to explore the 
mechanism(s) by which MGMT and BRCA1 regulates ERα-transcription activities. 
 
3.3.2 Antisense MGMT downregulates ERα expression and leads to cell cycle 
arrest 
To elucidate the mechanism for the absence of ERα+ MGMT- phenotype, MCF7 was 
transiently transfected with antisense-MGMT construct fused to GFP to deplete 
endogenous MGMT. Cells were harvested 48h post-transfection and analyzed for the 
protein profiles of ERα and MGMT. Unexpectedly, while MGMT protein levels decrease 
by ~ 40% decrease, the ERα protein is completely depleted, as shown in Fig 3.21.   
 
Fig 3.20  Absence of ER+/MGMT- phenotype in cells analyzed. Total cell 
lysates were  prepared from different cell lines. All the breast cancer cell lines 
are labeled in red. The blot was immunoblotted with MGMT (Mab3B8) and 












Fig 3.21 Antisense MGMT induces ‘knocked-out’ of ER protein. Antisense
MGMT was constructed by reversing the full-length insert into expression 
vector. The construct together with empty vector were transfected into MCF7 
cells. At 48h post transfection, cells were harvested and western analyzed for 
ER and MGMT. 
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As transient transfection has its drawback (ie. not all the cells are transfected), we next 
used the more efficient adenoviral infection method (these experiments were done in 
collaboration with my colleague Zou Hao) to investigate whether antisense MGMT 
transcripts do affect ERα gene expression. MCF7 cells were infected with adenoviral- 
antisense MGMT, control adenovirus vector (C-AV) or adenoviral expressing antisense 
p14ARF. Antisense p14ARF was used as a control for the infection procedure as MCF7 
does not express p14ARF. After 48h post-infection, the cells were collected and analyzed 
for mRNA expressions by semi-quantitative RT-PCR, protein expressions by 
immunoblot and cell-cycle profile by flow cytometric analysis.  
Fig 3.22A showed that with increasing MOI (multiplicity of infection) of antisense 
MGMT virus as compared to control virus, the mRNAs of ERα and estrogen-responsive 
gene c-myc are significantly reduced when the antisense MGMT RNA transcript was 
detected, as relative to the expression level of internal control GADPH gene.   
It was observed that at low infection index of 10 MOI, the MGMT protein only decreased 
slightly, accompanied by a slight drop in the ERα protein (Fig 3.22B). This is in 
agreement with the RT-PCR results. However, presence of increased MOI of antisense 
MGMT virus resulted in significant decrease in ERα and c-Myc (a downstream target of 
ERα) protein levels. No alteration in MGMT and ERα protein levels was observed in the 
control adenoviral vector or antisense p14ARF-infected cells. The GFP signal indicated 
presence of viral protein while the actin levels represented equal amount of samples 
loaded in the gels Fig 3.22B.  
To investigate the response of the cells to reduced MGMT expression, we analyzed the 
cell cycle profiles of the infected cells by fluorescence-activated cell sorter (FACS). As
E.
Fig 3.22  Relationship between antisense MGMT and ERα.
A. Semi-quantitative RT-PCR.  mRNA levels of respective genes were studied. 
Expression of antisense MGMT resulted in decreased levels of ERα and c-Myc
mRNAs. 
B. Western blots. Respective protein levels were analyzed upon the adenoviral expression 
of antisense MGMT in MCF7 cells. Introduction of antisense MGMT resulted in 
significant decrease in ERα and c-Myc.
C. Cell-cycle profile. Adenovirus-infected cells were analyzed by flow-cytometry. 
Antisense MGMT-infected cells showed significant growth arrest as they had low S-
phase and high G2/M cell populations.
D. ERE-reporter activity assay. Decrease in ERα-mediated activities could be observed 
when antisense MGMT was introduced into MCF7 cells
E. Schematic summary illustrating the effects of antisense MGMT on ERα.
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shown in Fig 3.22C, the decrease in endogenous MGMT resulted in cell cycle arrest at 
G0/G1 and G2/M stages with a significant decline in the S-phase cell populations as 
compared to both control adenoviral vector and antisense p14ARF-infected cells.  
In addition, to determine if the antisense MGMT can affect ERα-mediated transcription 
ERE-luciferase reporter activity assay was carried out (Fig 3.22D). ERE-luciferase 
reporter plasmid was transfected into the infected cells. Cells were allowed to grow in 
cdex medium to deplete estrogen-like compound in the normal growth media before 
stimulation with E2 (17-β-estradiol). In the presence of 10 MOI of antisense-MGMT 
virus, the ER-mediated reporter activity was reduced by half as compared to empty vector 
and at 20 MOI, the activity decreased by about 9-folds. There are some background 
enhancements of the luciferase activity from the empty vector infected cells as compared 
to the uninfected cells, but the mechanism for this observation is unknown.  
Collectively, these results implicate MGMT in the control of ERα gene and ERα-
regulated gene transcription in MCF7. Targeted reduction of endogenous MGMT thus 
results in ERα-mediated cell growth arrest. These data suggest that MGMT affects the 
ERα gene expression (as summarized in Fig 3.22E) and provides a plausible explanation 
for absence of ERα+/MGMT- phenotype. 
 
3.3.3 MGMT associates with ERα promoter 
To address how MGMT regulates the ER expression, we used chromatin 
immunoprecipitation (ChIP) analyses to determine whether MGMT can be recruited 
directly to ER promoter.  A few ERα- and ERα+ cell lines were subjected to ChIP assay 
using MGMT specific antibody Mab3B8. We found that ERα promoter was 
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immunoprecipitated only in cells expressing both ERα and MGMT and not in control cell 
line that does not express either ERα or MGMT (Fig 3.23A). Next we set to determine 
which region of the ERα promoter is preferentially bound by MGMT. ChIP assay was 
carried out in MCF7 cells and primers for the different regions of the ERα promoter (Fig 
3.23B ) were used to amplify the DNA isolated from the immunoprecipitates. The MGMT 
was found to bind to promoter A of ERα with strong preference for promoter PA2 region 
(depicted in Fig 3.23C) corresponding to –128 and –8 of the reported promoter P1 region 
of the of ERα promoter  (Green et al., 1986; Penolazzi et al., 1998; Penolazzi et al., 2000). 
MGMT has a lesser affinity for the PA1 fragment (which encompasses the PA2 region) and 
no interaction with PB1 located at promoter P3 of ERα promoter.  
It was reported that using the decoy strategy, putative regulatory properties were 
identified inside P1 canonical promoter between –128 and -8 and also at the upstream P3 
promoter (Penolazzi et al., 1998a). Decoy against P1 canonical promoter induced an 
inhibition of ERα gene transcription in MCF7 cells. Hence, it was suggested that the 
expression of ERα gene is directed by cis-element in P1 promoter for positive 
transcription. This 120bp PA2 region, which MGMT is associated to, is exactly the decoy 
used in the above experiment. This fragment contains CAAT (GCCAATG) and TATA 
(ACTTAAA) boxes.  In agreement with their findings, anti-sense MGMT resulted in 
reduction of ERα gene expression and consequently inhibit the transactivation of c-myc 
genes. This provides strong evidence that MGMT could be a transcription factor for ERα, 
thus providing an explanation for the absence of ERα+/MGMT– phenotype in the breast 
cancer cell lines analyzed. Whether MGMT binds to CAAT or the TATA boxes to 
regulate the ERα expression is as yet undetermined. 
Fig 3.23. MGMT associate with ERα promoter.
A.   ChIP assay using Mab3B8. ChIP showed that ERα promoter was 
immunoprecipitated only in cells expressing both ERα and MGMT.
B.         Schematic representation of the two ERα promoters. 
C.       ChIP assay using PabMGMT. ChIP showed the preferential association 





3.3.4 Regulation of ERα promoter by MGMT and BRCA1 upon DNA damages 
 
3.3.4.1 Inter-relationships among MGMT, ERα and BRCA1 upon DNA damage 
Both MGMT and BRCA1 (Breast cancer susceptibility gene1 product) are involved in 
DNA repair pathway and implicated in regulation of ERα function (Fan et al., 1999c; 
Teo et al., 2001b). Understanding the relationship among these three proteins upon 
different DNA damage insults is important for delineating the role of DNA damage-
induced tumorigenesis. Hence, we explored the effect of different DNA damage agents 
on the inter-relationships among the three proteins. MCF7 cells were exposed to low 
doses of γ-irradiation, alkylating agent NMU and oxidative agent hydrogen peroxide 
(H2O2) for 1h before recovering in fresh culture medium for harvest at different time 
durations. The cells were harvested for cell-cycle analysis and immunoblotting to detect 
expressions of MGMT, ERα, BRCA1, p53 and p21.  
Cell-cycle profiles showed that MCF7 cells underwent cell cycle delay as early as 6hr 
post γ-irradiation and a prominent G1 arrest by 24h. Growth arrest induced by γ-
irradiation is via the p53 regulatory pathway where induction of the p53 protein leads to 
the induction of potent cell cycle cyclin inhibitor p21WAF1 (see Fig 3.24B gamma panel).  
As for NMU treatment, cells are predominantly arrested at the G2/M phase at 24h post-
treatment. This growth arrest is a result of R-MGMT protein (see the protease V8 
sensitive MGMT proteins in fig 3.24B NMU panel), which inactivates the ERα protein 
through their direct interaction (Teo et al., 2001), as its disappearance at 24h after NMU 
treatment signals recovery from growth arrest. This further confirms the relationship 
between MGMT and ERα in estrogen-responsive cell growth regulations. Finally, the
Fig 3.24  Inter-relationships among MGMT, ERα and BRCA1 upon DNA damage.
A. Cell-cycle profiles. MCF7 cells which were γ-irradiated, NMU and H2O2-treated 
were analyzed. Profiles showed distinct growth arrest patterns for different 
treatments. Arrows in panels indicate start of cycle profile changes after 
treatment. The highlighted box in NMU panel showed cells recovering from 
growth arrest whereas in H2O2, it highlighted the similarity between H2O2 and  
antisense MGMT growth arrest (fig 3.22C ). 
B. Western blots. The boxed panels showed potential protein factors mediating its 
respective growth arrests. 
C. Semi-quantitative RT-PCR. mRNAs levels of treated cells were studied. The 
highlighted box showed the significant decrease of ERα mRNA in H2O2-treated 
cells
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H2O2-mediated growth arrest may arise from the gradual disappearance of ERα proteins 
(Fig 3.24B H2O2 panel) and reduced mRNA level (Fig 3.24C). This is analogous to that 
observed for the antisense MGMT experiments (section 3.3.3). BRCA1 immunoblot 
showed that H2O2 treatment resulted in an increased in the BRCA1 protein level, which 
was not observed for other two treatments. 
 
3.3.4.2 Phosphorylated BRCA1 displaces MGMT from ERα promoter upon  
exposure to oxidation damage 
Since we have shown that MGMT resides on ERα promoter, we could relate the 
disappearance of ERα to promoter regulation by MGMT especially in the H2O2-treated 
cells. To ascertain this, we performed ChIP assay to determine the cause for ERα protein 
disappearance. MCF7 cells were treated as before and the nuclei from cells were isolated 
for ChIP assay. With ChIP assay, we found that upon exposure to H2O2, MGMT 
dissociates from the ERα PA2-containing promoter region (Fig 3.25A).  Interestingly, we 
found that this region was bound by BRCA1 protein. This data indicates that BRCA1 
could displace MGMT from ERα promoter upon oxidation damage. This displacement 
would thus explain the decreased ERα gene transcription (as indicated by the reduced 
mRNA levels), protein levels and the resultant growth arrest in these cells.  
To understand the mechanisms of how BRCA1 protein levels are induced and how it 
displaces MGMT from ERα promoter after H2O2 treatment, we tested whether BRCA1 
expression is modified following H2O2 treatment. Semi- quantitative RT-PCR indicated 
no alteration in BRCA1 transcript levels at early time point (data not shown). This 
suggested that the protein may have undergone post-translational modifications. To test
B.
C.
Fig 3.25 Phosphorylated BRCA1 displaces  MGMT from ERα promoter 
upon oxidation damage. A. MGMT and BRCA-1 ChIP Assay. Nuclei were 
isolated from MCF7 cells after 1h treatment for ChIP assay using polyclonal 
MGMT and BRCA-1 antibodies. The highlighted box showed the inverse 
relationship between MGMT and BRCA-1 proteins present on the ERα promoter 
A (PA1 and PA2) in control and H2O2-treated cells. B and C. Independent 
MPM2 immunoprecipitation experiments. B. Highlighted box showing 
phosphorylation of MGMT in 6BG and MeI-treated MCF7 cells; and 
phosphorylation of BRCA-1 in H2O2-treated cells (also shown in C.)
C. MGMT in NMU-treated cells was also phosphorylated.
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this, we subjected the H2O2, 6BG and MeI-treated total cell lysates to IP using a specific 
antibody, MPM2 (α-MPM2) which recognizes a phosphorylated epitope 
(Serine/Threonine)-Proline, (S/T)-P. As shown in Fig 3.25B, significant amounts of 
MGMT proteins were recovered by the α-MPM2 antibody in 6BG and MeI-treated but 
not in H2O2-treated cells. Conversely, BRCA1 was precipitated with α-MPM2 only in 
H2O2-treated samples. Potentially, this data suggested that BRCA1 is phosphorylated 
upon oxidation damage and this phosphorylated BRCA1 is capable of displacing MGMT 
from the ERα promoter. This displacement led to reduced transcription of ERα gene 
mediated by MGMT and hence, resulted in growth arrest reminiscent of the antisense 
MGMT experiments.  We also showed that MGMT can be phosphorylated upon 6BG, 
MeI and NMU but not in H2O2 and γ-treated cells (Fig 3.25B and C). This indicates that 
MGMT may be phosphorylated upon conformation change. However, whether 
phosphorylation precedes conformation change or vice-versa remains to be clarified. 
Since the epitope recognized by α-MPM2 is phosphorylated S/T-P, examination of the 
MGMT protein sequence revealed two possible phosphorylation sites, one at the N-
terminal residue Ser14 and the other at C-terminal Ser201 (Fig 3.26). Taken together, we 
showed that MGMT can associate with ERα promoter region and up-regulate ERα 
expression. However, upon oxidation damage, this association is disrupted by 
phosphorylated BRCA1, resulting in reduced ERα protein level and growth arrest. On the 
other hand, during alkylation damage, MGMT is phosphorylated at the S-P motif with 
subsequent conformation changes. Hence, it no longer binds and regulates ERα 

















M D K D C E M K R T T L D S P L G K L E L S G C E Q G L H E I K L L G K G T S A A D A V E V P A P A  50
M A E T C K M K Y S V L D S P L G K M E L S G C E R G L H G I R L L S G K T P N T D P T E A P A T P  50
M A E I C K M K Y T V L D S P L G K I E L S G C E R G L H G I R F L S G K T P N T D P T E A P A C P  50
A V L G G P E - - - - P L M Q C T A W L N A Y F H Q P E A I E E F P V P A L H H P V F Q Q E S F T R  96
E V L G G P E G V P E P L V Q C T A W L E A Y F R E P A A T E G L P L P A L H H P V F Q Q D S F T R  100
E V L G G P E G V P E P L V Q C T A W L E A Y F H E P A A T E G L P L P A L H H P V F Q Q D S F T R  100
Q V L W K L L K V V K F G E V I S Y Q Q L A A L A G N P K A A R A V G G A M R G N P V P I L I P C H  146
Q V L W K L L K V V K F G E T V S Y Q Q L A A L A G N P K A A R A V G G A M R S N P V P I L I P C H  150
Q V L W K L L K V V K F G E M V S Y Q Q L A A L A G N P K A A R A V G G A M R S N P V P I L I P C H  150
R V V C S S G A V G N Y S G G - L A V K E W L L A H E G H R L G K P G L G G S S G L A G A W L K G A  195
R V V R S D G A I G H Y S G G G Q A V K E W L L A H E G I P T G Q P A S K G - L G L T G T W L K S S  199
R V I R S D G A I G N Y S G G G Q T V K E W L L A H E G I P T G Q P A S K G - L G L I G S W L K P S  199
G A T S G S P P A G R N                                        207
F E S T S S E P S G R N                                        211
F E S S S P K P S G         209
Fig 3.26 Sequence alignment of the Human, mouse and Rat MGMTs. 
Highlighted the S/T-P phosphorylation motifs, the ERα-interacting motif 
(LWKLL) and the active site PCHRVV
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3.3.4.3 MGMT augments ERα-mediated transcription 
Interestingly, it was reported BRCA1 selectively inhibits the ligand E2-activated ERα 
transcriptional activity in breast cancer cells, leading to inhibition of two endogenous 
ERE-related genes expression (encoding PS2 and cathepsin D) in ERα+ breast cancer 
cell lines. This finding suggests a tissue-specific function for BRCA1in regulating ERα 
activities (Fan et al., 1999b; Fan et al., 2001b; Zheng et al., 2001a).  
In contrast, it was observed that wild-type MGMT (wt MGMT) enhanced the 
transcription activity of ERα in ER-mediated transcription assays in most of the cases 
(Fig 3.27). Firstly, we tested the effect of wt MGMT and BRCA1 on the ERα-mediated 
transcriptional activity. ERE-luciferase reporter assay was carried out in MRC5SV-ERα 
cells (see section 3.2.6). While BRCA1 itself suppressed the reporter activity (Fig 3.28), 
we observed an approximately 5-fold increase in the activity for wt-MGMT and these 
tallied with the reported findings. Intriguingly, co-transfection of wt MGMT and BRCA1 
abrogates the inhibition imposed by BRCA1. This suggests that wt-MGMT can override 
the inhibition imposed by BRCA1. This result revealed a function for MGMT as a 
potential oncogene in opposition to the function of BRCA1 as a tumor suppressor  
(Cornelis et al., 1995a). 
 
3.3.5 Discussions 
The complexity of cell growth and regulation in mammals is evidenced by the immense 
factors and ‘cross-talks’ involved. One of the well-studied regulators of cell proliferation 
is the ERα which belongs to the large superfamily of nuclear receptors. Uncontrolled 
ERα functions will therefore expose proliferating cells towards genome instability as an


















Fig 3.27  Augmentation of  ERE-luc reporter assay by WT MGMT. 
ERE-reporter assay was performed in MCF7 cells using WT expression 




















Fig 3.28 wt-MGMT overriding BRCA-1 inhibition in ERE-reporter 
assay. The assay was carried out in MRC5SV-ERa cells where WT 
expression vector or BRCA-1 expression vector  was transfected or co-
transfected.
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increase in proliferation rate will reduce the time available for DNA repair. Moreover, 
single-stranded DNA presented during DNA replication is more susceptible to damage 
than double-stranded DNA and hence, there is this fundamental requirement to couple the 
functions of ERα, especially its primary role in transcription of genes related to cell 
proliferation, to DNA repair. The positioning of MGMT at active transcription sites 
would be the most effective way of regulating the ERα−mediated transcription activity as 
well as repair.  
Evidences suggest that ERα is linked to development and progression of mammary 
carcinoma in addition to its primary role in normal breast development (Yang et al., 
2001). Thus it is important to know how ERα expression is regulated. This thesis 
presented the first evidence of how MGMT plays a role in controlling the ERα activities 
as well as its gene expression.  
The relationship between MGMT and ERα was established based on the prevalence of 
ERα+/MGMT+ and the absence of ERα+/MGMT- phenotype from the various breast 
carcinoma cell lines analyzed. This is further supported by antisense MGMT experiment 
and MGMT-mediated enhancement of ERα-dependent ERE reporter transcription assay. 
Ligand-activated ERα interacts with co-activator, which possesses histone acetylase 
activity to modify local chromatin structure and result in increase transcription rate of 
target gene (Chen et al., 2001). It is intriguing to find if active MGMT has such a 
function in activating ERE transcription.  
Interestingly, BRCA1, which functions as a tissue-specific tumour suppressor (Cornelis 
et al., 1995), also plays a role in the negative regulation of estrogen-responsive genes. In 
that, BRCA1 was shown to inhibit ligand-dependent or ligand-independent ERα-
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mediated transcriptional activities via its direct interaction with ERα (Fan et al., 1999; 
Fan et al., 2001; Zheng et al., 2001). The interplay between BRCA1 and ERα has been 
implicated in tumorigenesis related to breast and ovary (Hilakivi-Clarke, 2000). 
However, the most reputed observation for BRCA1 is its involvement in DNA-damaged 
repair since BRCA1 is not a repair protein as compared to MGMT, implicating its role is 
indirect in maintaining genome integrity. The function of BRCA1 in regulated DNA 
damage repair is shown here to be specific for ER+ exposed to H2O2 where it initiates the 
growth arrest by displacing MGMT from the ERα promoter. However, this requires 
phosphorylation of the BRCA1 mediated by H2O2-induced kinases. With the 
displacement of MGMT by the BRCA1 protein on the ERα promoter upon oxidation 
damage, the transcription-activating role potentially played by MGMT is diminished. 
This brings about the halt to the cell cycle, a crucial consequence orchestrated for DNA 
repair. Furthermore, Fig 3.27 shows that MGMT not only stimulates ERα-mediated 
transactivation activities, it can also overcome the negative regulation imposed by 
BRCA1 (Fig 3.28).  All together, these observations establish a link or relationship 
among BRCA1, ERα and MGMT in the maintenance of genome integrity in ERα+ breast 
cells. Therefore, BRCA1 and MGMT would appear to function as a pair of tumour-
suppressor and oncogene in ERα+ breast cells. A working model illustrating how the 
inter-relationship among MGMT, ERα and BRCA1 regulate cell growth upon DNA 




Fig 3.29 Schematic summary of growth arrest pathways in ERα+/MGMT+ cells 
upon exposure to DNA damaging agents.
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3.4 Role of R-MGMT in the p53-MDM2 regulatory pathway 
3.4.1 Sequence homology between p53 and MGMT 
The p53 tumour suppressor is well known as guardian of the genome. It plays a crucial 
role in regulation of the cell cycle control upon DNA damage. In cancer, the loss or 
inactivation of p53 is observed in a large number of human tumours  (Green et al., 1986; 
Levine, 1997; Vousden and Lu, 2002). p53 protein is tightly regulated and kept at low 
level by the negative regulation through MDM2 as they form an autoregulatory feedback 
loop (Picksley and Lane, 1993; Wu et al., 1993) where p53 induces the transcription of 
MDM2, which in turn binds and inhibits transactivation domain of p53.  
Interestingly, we found that the exposed Mab 3C7 epitope shares high sequence 







Fig 3.30 Sequence alignment between p53 and MGMT. The MGMT aa 87-109 shares 
high sequence homology to the MDM2-binding domain at the N-terminal of p53 (aa12-
32) 
 
Sequence alignment of the p53 N-terminal and R-MGMT (aa 91 to 107) indicated that 
MGMT may bind to MDM2.  
The MDM2 protein, which promotes p53 degradation via the proteosome pathway, 






et al., 1992). The inactivated MGMT has been reported to be ubiquitinated and degraded 
via the ubiquitin-proteosomal pathway, although the molecular basis of the breakdown is 
unknown (Xu-Welliver and Pegg, 2002)..  
 
3.4.2 Direct interaction between MGMT and MDM2 
To examine the potential association of MGMT and MDM2, GST (glutathione-S-
transferase) fusion protein containing only this peptide domain of MGMT (aa87-109), 
GST-MGMT, and the recombinant maltose-binding protein fusion of first 125 amino 
acids of MDM2 [MBP-MDM2 (1-125)] were used for in vitro pull-down assay. As a 
positive control, the MDM2-binding domain of p53 fused to GST [GST-p53 (12-32)] was 
generated. Results in Fig 3.31 showed the MGMT fragment can bind to MDM2, similar 
to that of p53. It was report that the crucial residues in p53 binding to MDM2 are 
phenylalanine (F19), tryptophan (W23) and leucine (L26) (Kussie et al., 1996). Thus, any 
mutation involving any of these residues will be expected to disrupt the p53-MDM2 
association. With the sequence alignment mapping p53’s F19 and W23 corresponding to 
MGMT’s F94 and W100 respectively, we substituted F94 and W100 with alanine to 
check their binding efficiency. Indeed, the MGMT point mutants-MDM2 interactions 
were perturbed as expected (Fig 3.31). This data therefore supports the hypothesis that R-


















Fig 3.31 In vitro pull-down assay. GST-fusion peptides (wt and point-mutated 
fragments of MGMT) were used to bind to MBP-MDM2 (aa1-125) to check for direct 
interaction. p53 was used as positive control.
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lesion by MGMT exposes the p53 homologous domain for direct binding to cellular 
MDM2. 
The data obtained from in vitro pull-down assay confirmed that MGMT does interact 
with MDM2 via the QESFTRQVLWKLL domain (Fig 3.31) and mutations of the critical 
residues F94, W100 and double mutants F94/W100 abolished the interaction between 
MGMT and MDM2  
 
3.4.3 R-MGMT preferentially interacts with MDM2 in vivo 
To study the interaction between R-MGMT and MDM2 in vivo, we used derivatives of 
RKO cells in which p53 function was abrogated through expression of the viral E6 
oncoprotein (Scheffner et al., 1990). This cell line was selected to ascertain whether the 
interaction between MDM2 and MGMT is direct and independent of p53. We subjected 
RKO-E6 cells to 6BG treatment to generate R-MGMT. The normalized total lysates were 
then used to IP MDM2 and western blot analyzed for presence of MGMT proteins.  As 
shown in Fig 3.32a, MGMT was detected only in the 6BG 6h sample but not the control 
lanes (C6 and C24) or the mock control IP reaction. As revealed by the V8 assay in Fig 
3.32b, only R-MGMT but not the active MGMT was detected in BG-treated extracts as 
indicated by the characteristic 14 and 18kDa polypeptides. This data confirmed that 
cellular R-MGMT and MDM2 interact with each other. Since the MDM2-interacting 
domain in MGMT is similar to p53, we investigate if this MGMT peptide can compete 
out the interaction of p53 and MDM2 in vivo. U2-Os cells were subjected to IP with anti-
MDM2 antibody to pull down the p53-MDM2 complexes. The complexes were 
challenged with 50 or 100µg of MGMT peptide –VLWKLKVVK-. As shown in the Fig
Fig 3.32 R-MGMT preferentially interacts with MDM2. A. MDM2 
immunoprecipitation. RKO-E6 (MGMT+/p53-) cells were treated respectively and 
MDM2-IP . Western showed that MGMT could only be detected in BG 6h sample. 
B. V8 protease assay. The respective treated lysates of RKO-E6 were subjected to 
V8 protease assay. Upon BG treatment, R-MGMT was detected as characterized 
by the 18kDa and 14kDa peptides. C. Peptide competition and MDM2 
immunoprecipitation in U2-Os cells Lane 1, lysates were subjected to 
immunoprecipitation using anti-MDM2 (positive control). 50 or 100mg of MGMT 
peptide -VLWKLKVVK- was added to immunoprecipitation reactions for peptide 
competition (lanes 2 and 3). Result showed that R-MGMT can compete with p53 






















3.32c, while the p53 pulled down by MDM2 antibody was unperturbed in the control 
sample, the addition of MGMT peptides significantly reduced the interaction.  Hence, R-
MGMT can compete with p53 for interacting with MDM2.  
 
3.4.4 R-MGMT protects p53 from deactivation by MDM2  
The formation of R-MGMT/ MDM2 complex and the ability for the MGMT peptides to 
disrupt the interaction between p53 and MDM2 suggest a role for R-MGMT in the 
regulation of the p53-MDM2 regulatory loop. As p53 has been shown to be ubiquitinated 
and inactivated by MDM2, we investigate if the presence of R-MGMT could affect this 
regulatory process.  
Since tumour suppressor p14ARF was known to bind and inhibit the E3 ligase function of 
MDM2 (Honda and Yasuda, 1999), U2-Os -p14ARF stable inducible cells (from KH 
Vousden’s lab) was used to test and compare the effects of R-MGMT and p14ARF (as a 
positive control) on the ligase activity of MDM2. These cells were subjected to 6BG and 
proteasome inhibitor MG132 treatment with and without the induction of p14ARF. From 
Fig 3.33a, MG132 protects MDM2 from proteosomal degradation in concordance with 
the reported findings. In 6BG-treated cells, however, R-MGMT produced did not seem to 
stabilize MDM2 as proposed. One possible explanation for such observation could be due 
to insufficient level of endogenous R-MGMT produced for binding and stabilization of 
MDM2 as it is known that U2-Os cells have low endogenous MGMT level as well as the 
rapid degradation of R-MGMT that cannot be blocked by MG132. To discount such 
possibility, in vitro ubiquitination assay was performed in parental U2-Os cells which 
have no p14ARF expression. Here, U2-Os cells were co-transfected with increasing
Fig  3.33 R-MGMT protects p53 from de-activation by MDM2. 
A. U2OS-p14ARF inducible cells treated with proteosome inhibitor (PI) for 6hr. 
MDM2 is stabilized by proteosome inhibitor MG132 as well as p14ARF. 
B. U2-Os in vitro ubiquitination assay. U2-Os cells were transfected with 
respective constructs for 48h. Western blot analysis showed that p53 protein 
level was decreased with increasing MDM2. However, in the presence of 
MGMT-97 (i.e. mutant K107L MGMT), p53 was stabilized and protected from 
degradation by MDM2. 
C. MDM2-promoter reporter assay. Constructs of m-L (MDM2-promoter-
luciferase reporter) and expression plasmids for p53 and MGMT-97 were co-
transfected into U2-Os cells. Reporter activity was augmented in the presence 
of MGMT-97, which protects the endogenous p53 from inactivation by MDM2.





























amounts of plasmids encoding wild type MDM2, Flag-tagged p53, and MGMT mutant 
K107L (see section 3.1). A plasmid, pEGFP, encoding green fluorescent protein (GFP) 
was used as an indicator for transfection efficiency. 48h after transfection, the cells were 
harvested to examine the p53, MDM2 and MGMT protein levels by western blot. As 
expected, the p53 protein was down-regulated with increasing amounts of MDM2 (Fig 
3.33b, lanes 3-5). Interestingly, p53 was not degraded in the presence of MGMT mutant 
K107L. Furthermore, we observed stabilization of MDM2 proteins with the presence of 
R-MGMT (Fig 3.33b, compare lanes 6-8 and lanes 3-5).  These results suggest that R-
MGMT can protect p53 from MDM2-mediated degradation. Since MDM2 possesses 
ubiquitin E3 ligase activity that targets itself and p53, we postulate that R-MGMT 
stabilizes both proteins by blocking the E3 ligase via its 3C7 epitope domain.  
As R-MGMT can protect p53 from degradation by MDM2, we assess how this affects the 
transcriptional activities of p53.  To test this, U2-Os cells, which express wild-type p53 
and MDM2, were transiently co-transfected with p53-responsive MDM2-promoter-
luciferase reporter (m-L) construct and the p53 expression plasmids in the presence or 
absence of MGMT-mutant K107L. As shown in Fig 3.33c, the luciferase activity for the 
reporter increased when p53 was co-transfected with m-L (bar2). The background 
activity observed might possibly due to endogenous p53 protein activity (bar1). When 
MGMT-97 (ie. mutant K107L MGMT) was added, the p53-mediated transcription 
activity of the reporter was augmented (bar 3 and 4), suggesting competition between 
K107L and endogenous p53 for binding to MDM2. Thus, the K107L mutant protects the 
endogenous p53 from inactivation by endogenous MDM2, therefore resulting in an 
increase in p53 transcriptional activity, as shown in bar 3. The further increase in activity 
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as shown in bar 4 could be due to the introduction of exogenous p53. These data suggest 
that MGMT-K107L or R-MGMT protects p53 from being deactivated by MDM2. 
 
3.4.5 Relationship between R-MGMT and p53/MDM2 regulatory loop in ML-1  
As the above study ascribe a function for ectopically-expressed R-MGMT in the 
p53/MDM2 regulatory pathway, we decided to ascertain if endogenous R-MGMT 
reflects this property as well. ML-1 (myeloid leukemia cells) which has the MGMT+/wt 
p53 + phenotype was used as a model system. 
ML-1 was treated with various combinations of 6BG, MeI and γ-irradiation and analyzed 
for protein expression level of p53, MGMT, and p21 (a downstream effector of p53). Fig 
3.34 showed that upon γ-irradiation, a rapid and sustained induction of p53 was observed. 
However, if the cells were treated with BG prior to γ-irradiation, p53 induction was not 
sustained. In sharp contrast, pre-treatment with MeI before γ-irradiation resulted in 
markedly enhanced p53 induction and stability when compared to γ-irradiation alone. It 
would appear that while both BG and MeI can generate R-MGMT, contrasting effects 
were exerted on p53 stability. Presumably, the additional alkylation damage induced by 
MeI, as opposed to the non-DNA damaging BG, is responsible for these disparate 
observations. Since phosphorylation of p53 protein has been shown to enhance its 
stability after DNA damage; we therefore analyze the p53 phosphorylation status of p53 
in MeI and BG pre-treated cells. Interestingly, p53 in BG-γ cells is poorly phosphorylated 
at the serine position (Fig 3.35). This may explain why p53 is more stable in MeI rather 
than BG pre-treated cells. Surprisingly, pre-treatment of cells with MeI resulted in muted 





Fig 3.34 Western blot analyses for p53, MGMT and p21WAF1 in treated ML-1 
cells. Cells were treated with combination of BG, MeI and 2.5gy gamma (γ) for 
various time-points. Sustained p53 level was observed in MeI-γ but not in BG-γ. 
p21 level does not reflect p53 induction in pretreatment with BG and MeI. 
Fig 3.35 Effect of R-MGMT on the phosphorylation of S-15 of p53 in 
ML-1. Serine-phosphorylated (S15) p53 was detected after respective 
treatments of cells. The same western blot was subsequently probed with 




Although the low p53 induction in BG-γ treated cells appears to contradict our hypothesis 
that R-MGMT stabilizes p53, it would seem that additional mechanisms such as 
phosphorylation of p53 at S15 is necessary for its stability. In this aspect, 
phosphorylation of R-MGMT observed (chapter 3.3.4.2) may be important because the 
R-MGMT/p53/MDM2 may shield p53 phosphorylation as R-MGMT is heavily 
phosphorylated as well upon exposure to alkylating agents. 
 
3.4.6 Discussions 
After having known that the Mab3C7 epitope shares high sequence homology to p53 and 
that sequence alignment of the p53 N-terminal and amino acids 91 to 107 of MGMT 
indicates that MGMT may bind to MDM2, an attempt was made to model the MGMT 
interaction domain on MDM2. (This work was done in collaboration with Ben Li and 
Alvin Teo). The residues F94 to V105 of MGMT are able to form an amphipathic α-
helical structure (Fig 3.36). Computer-aided modeling of this domain revealed that 
residues F94 is located too far away from W100 as compared to F19 and W23 of p53. 
Moreover, the F94 residue is pointing at opposite direction away from the W100 site 
chain, these observations suggest that F94 may not interact with the same residues in 
MDM2 as compared to the F19 of p53. The other possible candidate may be R96 which 
possess a positive charge may make contact with negatively charge residues in MDM2. 
Detailed analyses of the computer-generated models reveal that the orientation of p53 
interacting helix and the MGMT interacting helix are in opposite direction (Fig 3.36 
middle panel). The side chains of residues implicated in the binding to MDM2 are 
pointing downwards in p53 but upwards in MGMT.  When modeled against MDM2 cleft 
Fig 3.36 Amphipathic α-helical domain of MGMT and p53 binding to MDM2 
(aa1-125). A. The MDM2 N-terminal domain forms a structure with a deep 
hydrophobic cleft. p53 peptides (aa19-25) binds as an amphipathic α-helix. The 
residues F19 and W23 are depicted in yellow and blue respectively.  B.Top panel, The 
modeling of MGMT peptide that binds MDM2, looking down the view amphipathic α-
helices of p53 and MGMT peptides. The W100 of MGMT is orientated in opposite 
direction as compared to p53, R96 of MGMT is pointing at the same direction as 
W100, it  may be involved in the binding to the MDM2 cleft. Middle panel, Side view 
of the p53 and MGMT helices. Both the side chains of F19 and W23 residues of p53 
are pointing downwards, wheareas, MGMT R96 and W100 are facing up. Lower panel,
alignment of th ep53 and MGMT helix structure suggest that MGMT may not bind as
tightly to the MDM2 cleft as p53. This is due to the orientation of the side-chains of 
MGMT peptides. F94 of MGMT maybe interacting to residues in MDM2 cleft differ 
from p53 as its side chain is pointing at an opposite direction to F19 on p53, in 
















(Fig 3.36 lower panel), it was noted that MGMT residues do not fit tightly to the cleft, 
since all the side-chain are facing the opposite directions.  This modeling indicates that 
MGMT may not have strong affinity to MDM2 or that it may interact with different sets 
of residues within MDM2 cleft.  
The physiological interaction between R-MGMT and MDM2, however, was confirmed 
with in vivo immunoprecipitation experiments. In addition, immunoprecipitation 
experiments with peptide competition demonstrated that MGMT could potentially 
compete with p53 for interaction with MDM2 via its QESFTRQVLWKLL domain. A 
schematic summary depicting the relationship among p53, MDM2 and R-MGMT is 
illustrated in Fig 3.37.  
Though interaction between R-MGMT and MDM2 was confirmed, MGMT may not be a 
substrate for MDM2 in ubiquitination and subsequent degradation. 
In tumour cells where p53 proteins are inactivated by their binding to MDM2, these 
observations can be important and useful for screening drugs that target the re-activation 
of the p53 function.  
 

















Chapter 4  Conclusion 
 
The human O6-methylguanine methyltransferase (MGMT) is an error-free DNA repair 
enzyme that rapidly eliminates the mutagenic O6-methylguanine lesion. MGMT transfers 
the alkyl group from O6 –alkylguanine in DNA to a cysteine acceptor C145 at its active 
site –PCHRV-sequence. The cysteine acceptor is not regenerated and each MGMT 
molecule can only repair once. My results show why such an uneconomic repair 
mechanism is evolved.  
In my thesis, I have shown that active-site alkylated MGMT, R-MGMT, adopts a 
conformation change which renders the protein susceptible to protease V8 cleavage. Such 
an altered conformation exposes the domain surrounding the residues 91-107 which 
contains the monoclonal antibody 3C7 recognition epitope. For certainty, R-MGMT is 
not just meant for ubiquitination, followed by its degradation by the proteosomes after 
repair of the O6meG (Xu-Welliver and Pegg, 2002). This suicidal repair mechanism 
transforms the MGMT protein to a transcription repressor by exposing its LWKLL motif, 
found in the co-activator-receptor interacting box, to interact directly with the estrogen 
receptor alpha (ERα) and inactivate it from activation by co-activators. This leads to the 
repression of ERα-mediated transcription and proliferation in cells expressing both 
MGMT and ERα. My data has shown that indeed, R-MGMT, upon alkylation damage 
(such as MeI) or treatment with 6BG, can inhibit the function of ERα in its ERα-
mediated transcription.  
Surprisingly, R-MGMT also functions as a co-repressor not only for ERα but also 
glucocorticoid receptor (GR). It is known that ERα and GR are antagonistic to each 
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other. In the HeLa.CCL2 cells, R-MGMT binds to GR and overrides the ligand 
(dexamathsone)-mediated growth repression. It is yet unknown whether the HPV 
infection in these cells utilize MGMT in modulating GR functions since GR activities are 
critical in HPV transformation. Similarly, it is yet unknown why SV40 transformation 
often lead to down-regulation of MGMT expression.  
Why R-MGMT has a function in regulation of nuclear receptors (NRs) is unknown. 
However, the Ada protein may provide the clues since it resembles the human MGMT as 
a repair factor and transcription regulator, even though these activities are from two 
separate domains. Why MGMT is so specific for ERα regulation (at ERE and ERα 
promoter) will require an extensive understanding of how NRs are evolved in mammalian 
cells.  
My data also showed that R-MGMT can interact directly with MDM2 (an oncoprotein) 
via the exposed domain in R-MGMT, which shares high homology to tumour suppressor 
protein p53. The binding of R-MGMT to MDM2 is of significant interest, particularly 
when it resembles the MDM2/ p53 interaction. Such an interaction inhibits the function 
of MDM2 as an ubiquitin E3 ligase and stabilizes the p53 protein. However, the function, 
if any, behind such interaction between R-MGMT and MDM2, is yet to be determined.  
The active MGMT, on the other hand, plays a notable role in cell regulation and growth 
especially in ERα+ cells. It is characterized herein as a potential transcription activator of 
the ERα gene whereby it resides on the ERα promoter, driving transcription of the ERα 
gene. However, upon oxidation damage, BRCA1 (breast cancer susceptibility gene) 
protein becomes phosphorylated and displaces MGMT from ERα promoter, resulting in 
the attenuation of the ERα transcription and arrest of ERα-mediated cell cycle.  
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The above summary indicates the complexity or versatility of the MGMT/R-MGMT 
repair pathway in cell regulation. In other words, the suicidal repair mechanism, although 
uneconomical, enables a protein to have two distinct functions: DNA repair and 
regulation of hormone receptors.  
In conclusion, MGMT is herein characterized to be an important cell growth regulator in 
ER+/MGMT+ breast cells, in which different DNA damage signals are transduced via 
MGMT/R-MGMT to control the growth of these cells. A working model illustrating the 
multifaceted role of MGMT/R-MGMT in cellular regulation upon DNA damage is 

















































































Fig 4.1  Multifaceted Role of MGMT / R-MGMT 
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Abstract
5-Methylcytosine residues in the DNA (DNA methylation) are formed
from the transfer of the methyl group from S-adenosylmethionine to the
C-5 position of cytosine by the DNA-(cytosine-5) methyltransferases
(DNMTs). Although regional hypermethylation and global hypomethyla-
tion of the genome are commonly observed in neoplastic cells, how these
aberrant methylation patterns occur remains unestablished. We report
here that sulfonate-derived methylating agents, unlike N-methylnitro-
sourea or iodomethane, are potent in depleting DNMT1 proteins in human
cells, in addition to their DNA-damaging properties. Their effects on
cellular DNMT1 are time and dosage dependent but independent of cell
type. Unlike -irradiation, these agents apparently do not activate the
p53/p21WAF1 DNA damage response pathway to deplete the DNMT1
proteins because cells with wild-type, mutated, or inactivated p53 behave
similarly. However, cell cycle analysis and protease assay studies strongly
suggest that methylmethanesulfonate may activate a cellular protease to
degrade DNMT1. These results explain why reported observations on the
effect of alkylating agents on DNMT1 activities in human cells vary
significantly and provide a crucial link to understand the mechanism
behind genomic hypomethylation.
Introduction
Although the 5-MeC3 residues constitute only 2–3% of the mam-
malian genome, they serve important roles in gene regulation such as
imprinting, long-term silencing of tissue-specific genes, and X-chro-
mosome inactivation. 5-MeC (DNA methylation)-mediated silencing
may be accomplished by methylated cytosine binding proteins (i.e.,
MeCP2), which target histone deacetylase to condense the region of
DNA containing 5-MeC (1), or the inability of transcription factors to
bind methylated promoter sites (2, 3). Aberrant methylation, in the
forms of regional hypermethylation (4) and global hypomethylation
(5) of the genome, are commonly observed in neoplastic cells. They
are nonrandom and tumor type-specific (6), suggesting that improper
methylation contributes to cancer initiation or progression. Two caus-
ative roles for methylation in tumor progression have been observed:
(a) silencing of tumor suppressor genes, such as p21WAF1, p16INK4a,
or Rb, correlate with hypermethylation of their promoter regions in
certain tumors (7); and (b) increased deletion mutation rates leading to
genomic instability are associated with global hypomethylation of the
genome (8). The observation that a DNMT gene is mutated in the ICF
(immunodeficiency, centromeric instability, facial abnormalities) syn-
drome, which is characterized by hypomethylation and chromosome
breakage (9–12), strengthens the role of DNA methylation in human
diseases.
How aberrant methylation occurs in tumor cells remains unestab-
lished. A likely candidate for study is the DNA-(cytosine-5) methyl-
transferase DNMT1, which constitutes 90% of methylation activi-
ties in the mammalian cells (13, 14). It processes the maintenance
methylase activities necessary for normal cell growth, as well as
unusual de novo methylase activities (15). Therefore, any alterations
in the cellular level of DNMT1 protein may potentially lead to
changes in DNA methylation patterns. In this study, we addressed the
question of whether mutagens can affect the DNMT1 protein by
studying the levels of DNMT1 in cells exposed to -irradiation and
alkylating mutagens. We report here that sulfonate-derived methylat-
ing agents, such as MMS and DMS, are potent in depleting DNMT1
proteins in the human cells, a novel addition to their abilities in
producing alkylation lesions, such as apurinic sites and single- and
double-strand breakage in the DNA (16). This hitherto unknown
property of sulfonate-derived methylating agents suggests the multi-
plicity of these agents in tumor-causing actions.
Although DNMT1 and p21WAF1 proteins are shown to share an
inverse relationship throughout the cell cycle and after exposure to
-irradiation, this relationship is not observed during MMS treatment,
which induces DNMT1 depletion in cells with Wt, mutated, or inac-
tivated p53. Results from cell cycle analysis and protease assay
suggest that the effects of MMS may be direct or indirect, possibly via
the modification of DNMT1 or activation of a cellular protease to
degrade DNMT1 proteins. These results may explain why reported
observations on the effect of alkylating agents on DNMT1 activities in
the human cells vary significantly (17) because MMS and DMS have
a distinctive effect on the cellular DNMT1 proteins in a time- and
dosage-dependent manner as compared with NMU and MeI.
Materials and Methods
Treatment of Cells with Mutagens. All cell lines were obtained from
American Type Cell Culture and cultured as specified by American Type Cell
Culture. MMS, MeI, DMS, and NMU were purchased from Sigma Chemical
Co.-Aldrich. The cells were grown to 50% confluence before commencing
drug treatment. Stock solutions of all drugs were made in serum-free media
and added to the cells for the indicated times. -Irradiation was done using a
60Co source at room temperature.
Cell Lysis and Western Analysis. Cell pellets were lysed in a modified
RIPA buffer [50 mM Tris (pH 8.0), 0.3 M NaCl, 10 mM EDTA, 50 mM NaF,
0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, and 0.2 mM phenylmeth-
ylsulfonyl fluoride] by sonication. The lysates were then centrifuged at 14,000
rpm for 20 min at 4°C (Eppendorf), and the supernatant was recovered. Protein
concentrations were determined by Lowry assay. Cell lysates (100 g) were
resolved on 6.9 and 12% SDS-PAGE. After electrophoresis, the proteins were
transferred to polyvinylidene difluoride membranes (Bio-Rad). Western anal-
yses were performed as described (18). Monoclonal antibody Mab.2E10 for
DNMT1 was described previously (18). Mab.D01 for p53 and Mab.PC10 for
PCNA detections were from Santa Cruz Biotechnology. Mabs to actin (clone
C4) and p21WAF1 (clone 70) were from Boehringer Mannheim and Transduc-
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The Modified Human DNA Repair Enzyme O6-Methylguanine-DNA
Methyltransferase Is a Negative Regulator of Estrogen
Receptor-Mediated Transcription upon
Alkylation DNA Damage
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Cell proliferation requires precise control to prevent mutations from replication of (unrepaired) damaged
DNA in cells exposed spontaneously to mutagens. Here we show that the modified human DNA repair enzyme
O6-methylguanine-DNA methyltransferase (R-MGMT), formed from the suicidal repair of the mutagenic
O6-alkylguanine (6RG) lesions by MGMT in the cells exposed to alkylating carcinogens, functions in such
control by preventing the estrogen receptor (ER) from transcription activation that mediates cell proliferation.
This function is in contrast to the phosphotriester repair domain of bacterial ADA protein, which acts merely
as a transcription activator for its own synthesis upon repair of phosphotriester lesions. First, MGMT, which
is constitutively present at active transcription sites, coprecipitates with the transcription integrator CREB-
binding protein CBP/p300 but not R-MGMT. Second, R-MGMT, which adopts an altered conformation,
utilizes its exposed VLWKLLKVV peptide domain (codons 98 to 106) to bind ER. This binding blocks ER from
association with the LXXLL motif of its coactivator, steroid receptor coactivator-1, and thus represses ER
effectively from carrying out transcription that regulates cell growth. Thus, through a change in conformation
upon repair of the 6RG lesion, MGMT switches from a DNA repair factor to a transcription regulator
(R-MGMT), enabling the cell to sense as well as respond to mutagens. These results have implications in
chemotherapy and provide insights into the mechanisms for linking transcription suppression with transcrip-
tion-coupled DNA repair.
Exposure to environmental mutagens, such as UV irradia-
tion and N-nitroso compounds, accounts for 80% of the human
cancer incidence (30). The effectiveness of our cells’ attempts
to repair the DNA lesions inflicted by mutagens on our DNA
before DNA replication is fundamentally linked to manifesta-
tion of the disease through this etiological pathway. The p53
protein is critical here for maintaining genomic integrity, since
its induction upon DNA damage enables the cell to acquire
sufficient time to repair the damaged DNA by halting cell cycle
progression through its effector, the cell cycle-dependent ki-
nase inhibitor p21WAFI (11, 15). However, p53 appears to be
only a downstream effector of this DNA damage response
pathway in the cell, since cellular factors, such as the hChk1
and hChk2 (human homologs of the yeast RAD53 and CDS1
proteins), are shown to stabilize p53 through phosphorylation
upon exposure to mutagens (6, 14, 35). While much is known
about cell regulation where external stimuli are transduced via
the membrane receptors and kinase cascades to activate the
nuclear DNA (8), knowledge of reciprocal pathways through
which DNA, when it is damaged, signals cellular response
through immediate factors remains circumstantial.
The high-fidelity property of DNA and RNA polymerases
enables them to serve as important signaling factors for the
integrity of the DNA as they are arrested at the bulky DNA
lesions inflicted by mutagens (33) while processing along the
DNA to carry out their functions. However, what could be an
effective signaling factor for the DNA containing subtle DNA
lesions that do not arrest the polymerases? DNA repair en-
zymes are molecular sensors of damaged DNA in the cell,
since they recognize and repair damaged DNA. It would be a
very effective survival strategy if the same DNA repair enzyme
could also be a signaling molecule as well as a regulator for the
presence of damaged DNA in the cells. The Escherichia coli
ADA protein is a unique example, exhibiting these properties
in protecting the bacteria from the cytotoxic effects of the
phosphotriester lesions in the DNA that are induced by alkyl-
ating agents. Upon repairing the phosphotriester lesions by
transferring the alkyl group from the phosphotriester lesion to
the active site of the phosphotriester repair domain at its N
terminus, the alkylated protein becomes a transcription acti-
vator for its own synthesis. This increases the amount of the
ADA protein in the bacterial cell for protection against further
damage from alkylating agents (38, 39). Unfortunately, such an
elegant DNA repair and response pathway appears to be lim-
ited to the prokaryotes, since homologs of the ADA protein
are not found in the eukaryotes (44).
Nevertheless, the O6-methylguanine-DNA methyltransferase
(MGMT), which has an alkyl transfer repair mechanism sim-
ilar to that of the E. coli ADA protein, is present in all organ-
isms. It protects cells from the mutagenic and cytotoxic effects
of alkylating carcinogens (10) by transferring the alkyl group of
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DNA lesions that halt RNA polymerase during transcription are preferentially repaired by the nucleotide
excision repair pathway. This transcription-coupled repair is initiated by the arrested RNA polymerase at the
DNA lesion. However, the mutagenic O6-methylguanine (6MG) lesion which is bypassed by RNA polymerase
is also preferentially repaired at the transcriptionally active DNA. We report here a plausible explanation for
this observation: the human 6MG repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) is
present as speckles concentrated at active transcription sites (as revealed by polyclonal antibodies specific for
its N and C termini). Upon treatment of cells with low dosages of N-methylnitrosourea, which produces 6MG
lesions in the DNA, these speckles rapidly disappear, accompanied by the formation of active-site methylated
MGMT (the repair product of 6MG by MGMT). The ability of MGMT to target itself to active transcription
sites, thus providing an effective means of repairing 6MG lesions, possibly at transcriptionally active DNA,
indicates its crucial role in human cancer and chemotherapy by alkylating agents.
DNA in unwound (active) chromatin at sites of transcription
or replication is vulnerable to damage induced by chemicals
and irradiation (3, 7, 32, 34). Left unrepaired, these DNA
lesions affect cell survival. First, they either inhibit DNA poly-
merase (11) or are miscoded by the polymerase during DNA
replication (1, 30, 31). Second, they can halt RNA polymerase
during transcription of active genes (44). For example, to over-
come the possible lethal blockage of transcription due to the
arrested RNA polymerase at the thymine-thymine (T-T) pho-
todimer (or bulky DNA lesions) formed in the transcribing
DNA strand by irradiation, bacteria use the MFD protein (a
transcription repair coupling [TRC] factor), which interacts
with the arrested RNA polymerase at the lesion and recruits
the uvrABC repair proteins (bacterial nucleotide excision re-
pair [NER] proteins) for its repair (41, 42). In eukaryotes,
similar preferential repair of bulky DNA lesions in the tran-
scribing DNA strand by the NER pathway, i.e., TRC, has been
reported. However, the details of the mechanism appear to be
much more complicated than the prokaryotic counterpart
since coupling of eukaryotic DNA repair to transcription
should involve several stages, such as nucleosome remodelling
(e.g., the yeast RAD26 protein as a Swi2/Snf2-like ATPase
[50]), assembling of the multicomponent preinitiation complex
(e.g., the RAD25 helicase as a subunit of TFIIH [50]), and
possibly others (e.g., the unestablished role of the human
ERCC6 protein as a DNA-dependent ATPase [43]). Further-
more, TRC may be interrelated between different DNA repair
pathways as mismatch repair-defective human cells may lack
TRC of the T-T photodimer by NER (33).
The N-nitroso compounds are carcinogens to which we are
all exposed because they are synthesized naturally in our gas-
trointestinal tract. They are also cytotoxic, and some of them,
notably bis-chloroethylnitrosourea, are used in cancer chemo-
therapy. They owe their carcinogenic and toxic properties to
their ability to alkylate the 6-oxygen of guanine in DNA. Cells
protect themselves from these compounds with a DNA repair
protein, O6-methylguanine-DNA methyltransferase (MGMT),
which removes the alkyl group from the O6-alkylguanine and
transfers it to a cysteine residue in the active site of the trans-
ferase (a suicidal repair protein) (37). Interestingly, the muta-
genic O6-alkylguanine lesions are also preferentially repaired
at transcriptionally active DNA. This was shown recently by
direct measurements of the O6-ethylguanine residues formed
and repaired in specific genes of rat cells treated with N-
ethylnitrosourea (48), which agree with the findings for Esch-
erichia coli, by quantifying the frequency of GC-to-AT point
mutations resulting from the miscoding behavior of the O6-
methylguanine (6MG) residues formed in the DNA of bacteria
exposed to methylating agents (12, 42). However, unlike the
arrested RNA polymerase-DNA lesion complex-mediated re-
moval of bulky lesions in the transcribing DNA strand by NER,
the O6-alkylguanine base in DNA does not arrest RNA poly-
merase. This results in directing the misincorporation of uri-
dine at this site (12).
To address the question of how 6MG residues are prefer-
entially repaired at transcriptionally active DNA by MGMT,
we report here a detailed immunocytological study of the dis-
tribution of the repair protein within the cell nucleus. Studies
with polyclonal antibodies specific for the N and C termini of
MGMT show that MGMT is strongly localized in small foci
(speckles or embedded structures) in the nucleus. Although
this strong localization was not seen when monoclonal anti-
bodies (MAbs) to inner regions of the transferase were used,
the evidence is that this localization is a genuine phenomenon.
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ABSTRACT: Human O6-methylguanine-DNA methyltransferase (MGMT) repairs DNA by transferring alkyl
(R-) adducts from O6-alkylguanine (6RG) in DNA to its own cysteine residue at codon 145 (formation of
R-MGMT). We show here that R-MGMT in cell extracts, which is sensitive to protease V8 cleavage at
the glutamic acid residues at codons 30 (E30) and 172 (E172), can be specifically immunoprecipitated
with an MGMT monoclonal antibody, Mab.3C7. This Mab recognizes an epitope of human MGMT
including the lysine 107 (K107) which is within the most basic region that is highly conserved among
mammalian MGMTs. Surprisingly, the K107L mutant protein is repair-deficient and readily cleaved by
protease V8 similar to R-MGMT. We propose that R-MGMT adopted an altered conformation which
exposed the Mab.3C7 epitope and rendered the protein sensitive to protease V8 attack. This proposal
could be explained by the disruption of a structural “salt-link” within the molecule based on the available
structural and biochemical data. The specific binding of Mab.3C7 to R-MGMT has been compared with
the protease V8 method in the detection of R-MGMT in extracts of cells treated with low dosages of
methyliodide (SN2) and O6-benzylguanine. Their identical behaviors in producing protease V8 sensitive
R-MGMT and Mab.3C7 immunoprecipitates suggest that probably methyl iodide (an ineffective agent in
producing 6RG in DNA) can directly alkylate the active site of cellular MGMT similar to O6-benzylguanine.
The effectiveness of MeI in producing R-MGMT, i.e., inactivation of cellular MGMT, indicates that this
agent can increase the effectiveness of environmental and endogenously produced alkylating carcinogens
in producing the mutagenic O6-alkylguanine residues in DNA in ViVo.
Alkylation of the exocyclic oxygen of guanine in DNA,
whether by environmental exposure or by cancer chemo-
therapeutic agents, is repaired by O6-methylguanine-DNA
methyltransferase [MGMT, reviewed by Yarosh (1985) and
Pegg (1990)], which transfers the alkyl group from O6-
alkylguanine residues in DNA to its own cysteine centered
in the active site. This active site alkylated protein, R-
MGMT, is inactive and is not regenerated to MGMT. In
humans the expression of MGMT is barely inducible, and
therefore the repair capacity of a cell is determined by the
amount of MGMT and its constitutive rate of synthesis.
MGMT rapidly repairs O6-methyl- and ethylguanine
residues in DNA, although longer chain or bulkier derivatives
are repaired with lesser efficiency. It is generally believed
that the observed loss of MGMT repair activities, or the
formation of R-MGMT, in mammalian cells treated with
alkylating agents are the result of MGMT repair of the O6-
alkylguanine residues produced in the DNA by alkylating
agents, i.e., by an indirect pathway. However, the observa-
tion that O6-benzylguanine (6BG), which does not damage
DNA, can effectively inactivate MGMT in human cells at
micromolar concentrations (Dolan et al., 1990) suggests that
cellular MGMT can be directly alkylated at its active site
without DNA damage. It is of particular interest to examine
whether alkylating agents, apart from damaging DNA, can
directly inactivate cellular MGMT as compared to the
observation in Vitro (Brent, 1986). This can be studied by
comparing the effectiveness of low dosages of SN1 and SN2
alkylating agents in producing R-MGMT (or a loss of
MGMT activity) in cells, since SN2 alkylating agents are
inefficient in producing O6-alkylguanine in DNA (Lawley,
1984). This study is also relevant to human cancer because
SN2 agents such as methyl halides are potential human
carcinogens (Foster et al., 1985) which are common in the
environment (Harper, 1985; Gschwend et al., 1985). Such
study, however, requires a sensitive method to distinguish
inactive R-MGMT from active MGMT.
R-MGMT is stable in purified preparations and is not
spontaneously degraded (Belanich et al., 1994; Pegg et al.,
1991). The fate of R-MGMT in ViVo, however, varies among
cells. Immunoreactive R-MGMT is lost within the first few
hours from HT29 colon adenocarcinoma cells (Belanich et
al., 1994; Pegg et al., 1991) and human rhabdomyosarcoma
xenografts grown in mice (Belanich et al., 1996), whereas
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A method for simultaneous identification of human active and 
active-site alkylated O6-methylguanine-DNA methyltransferase and 
its possible application for monitoring human exposure to alkylating 
carcinogens. 
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Cells resist the major mutagenic effects of alkylating agents by the action of O6-
methylguanine-DNA methyltransferase (MGMT), which transfers the alkyl (R) 
group of O6-alkylguanine, produced in DNA by these chemicals, to a cysteine 
residue in its active site (formation of R-MGMT). We demonstrate that cellular R-
MGMT (which represents a record or memory within the cells exposed to these 
chemicals) can be assayed by its sensitivity toward proteolysis by protease V8. 
The possible use of this assay for monitoring exposure to alkylating carcinogens 
was investigated by using cultured cells and a preliminary study with the use of 
human blood from normal subjects and patients undergoing chemotherapy. 
Cultured cell experiments show that R-MGMT is sufficiently stable for the 
monitoring purpose and its level bears a dose-response relationship to the 
concentrations of the alkylating agent used. Interestingly, experiments with blood 
from patients undergoing chemotherapy show a gradual formation of R-MGMT in 
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and an induced MGMT deficiency 
in cyclophosphamide-treated patients. The use of this methodology, which allows 
for the possible quantification of active MGMT (cellular DNA repair capacity) 
and R-MGMT (recent exposure) simultaneously, in monitoring human exposure 
to alkylating carcinogens is discussed. 
 
